## Epidemiology and etiology of Parkinsonâ€₅Misease: a re

European Journal of Epidemiology 26, 1-58 DOI: 10.1007/s10654-011-9581-6

Citation Report

#	Article	IF	CITATIONS
2	The Emerging Health Benefits of Coffee with an Emphasis on Type 2 Diabetes and Cardiovascular Disease. European Endocrinology, 2010, 9, 99.	0.8	22
3	Detection, Quantification, and Microlocalisation of Targets of Pesticides Using Microchannel Plate Autoradiographic Imagers. Molecules, 2011, 16, 8535-8551.	1.7	22
4	Why age (and timing) really matters in developing drugs for neurodegenerative disease. Therapy: Open Access in Clinical Medicine, 2011, 8, 459-461.	0.2	0
5	In search of the causes of Parkinson's disease, seasons 1 to 4. European Journal of Epidemiology, 2011, 26, 505-509.	2.5	1
6	Diabetes and Risk of Parkinson's Disease. Diabetes Care, 2011, 34, 2614-2623.	4.3	181
7	Using genome-wide complex trait analysis to quantify 'missing heritability' in Parkinson's disease. Human Molecular Genetics, 2012, 21, 4996-5009.	1.4	176
8	Brain rust: Recent discoveries on the role of oxidative stress in neurodegenerative diseases. Nutritional Neuroscience, 2012, 15, 94-102.	1.5	21
9	Mechanism of BAG1 repair on Parkinson's disease-linked DJ1 mutation. Journal of Biomolecular Structure and Dynamics, 2012, 30, 1-12.	2.0	12
10	Furthering the understanding of olfaction, prevalence of loss of smell and risk factors: a population-based survey (OLFACAT study). BMJ Open, 2012, 2, e001256.	0.8	162
11	Age- and diet-dependent requirement of DJ-1 for glucose homeostasis in mice with implications for human type 2 diabetes. Journal of Molecular Cell Biology, 2012, 4, 221-230.	1.5	96
12	Stem cells and regenerative therapies for Parkinson's disease. Degenerative Neurological and Neuromuscular Disease, 2012, 2, 79.	0.7	3
13	Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinson's disease subjects. Neurological Research, 2012, 34, 669-676.	0.6	57
14	The Bad, the Good, and the Ugly about Oxidative Stress. Oxidative Medicine and Cellular Longevity, 2012, 2012, 1-13.	1.9	60
15	Deep Brain Stimulation for Movement Disorders. Frontiers in Integrative Neuroscience, 2012, 6, 2.	1.0	56
16	Dementia and sleep disturbances. Aging Health, 2012, 8, 65-78.	0.3	3
17	Inflammation in Parkinson's Disease. Advances in Protein Chemistry and Structural Biology, 2012, 88, 69-132.	1.0	154
18	Late-onset Parkinsonism in NFÂB/c-Rel-deficient mice. Brain, 2012, 135, 2750-2765.	3.7	66
19	Epidemiology, diagnosis and differential diagnosis in Parkinson's disease tremor. Parkinsonism and Related Disorders, 2012, 18, S90-S92.	1.1	75

	СІТАТ	CITATION REPORT	
#	Article	IF	Citations
20	Head injury and Parkinson's disease: A populationâ€based study. Movement Disorders, 2012, 27, 1632-10	635. 2.2	42
21	Head injury and the risk of Parkinson's disease. Movement Disorders, 2012, 27, 1592-1594.	2.2	1
22	Pesticide exposure and Parkinson's disease: Epidemiological evidence of association. NeuroToxicology, 2012, 33, 947-971.	1.4	205
23	The outdoor air pollution and brain health workshop. NeuroToxicology, 2012, 33, 972-984.	1.4	422
25	Associations of welding and manganese exposure with Parkinson disease. Neurology, 2012, 79, 1174-118	30. 1.5	72
26	Molecular Chaperones and Co-Chaperones in Parkinson Disease. Neuroscientist, 2012, 18, 589-601.	2.6	47
27	Pediatric indications for deep brain stimulation. Child's Nervous System, 2012, 28, 1701-1714.	0.6	42
28	Understanding the link between cancer and neurodegeneration. Journal of Geriatric Oncology, 2012, 3, 58-67.	0.5	43
29	Industrial toxicants and Parkinson's disease. NeuroToxicology, 2012, 33, 178-188.	1.4	121
30	Salidroside protects PC12 cells from MPP+-induced apoptosis via activation of the PI3K/Akt pathway. Food and Chemical Toxicology, 2012, 50, 2591-2597.	1.8	53
31	Occupational exposure to pesticides and Parkinson's disease: A systematic review and meta-analysis of cohort studies. Environment International, 2012, 46, 30-43.	4.8	143
32	Leukocyte-subset counts in idiopathic parkinsonism provide clues to a pathogenic pathway involving small intestinal bacterial overgrowth. A surveillance study. Gut Pathogens, 2012, 4, 12.	1.6	46
33	X-Ray Fluorescence Imaging: A New Tool for Studying Manganese Neurotoxicity. PLoS ONE, 2012, 7, e48899.	1.1	39
34	Is there a relation between extremely low frequency magnetic field exposure, inflammation and neurodegenerative diseases? A review of in vivo and in vitro experimental evidence. Toxicology, 2012, 301, 1-12.	2.0	56
35	Smoking and alcohol consumption in relation to risk of thyroid cancer in postmenopausal women. Cancer Epidemiology, 2012, 36, 335-340.	0.8	39
36	Parkinson's Disease. Sub-Cellular Biochemistry, 2012, 65, 389-455.	1.0	283
37	Rodent Models and Contemporary Molecular Techniques: Notable Feats yet Incomplete Explanations of Parkinson's Disease Pathogenesis. Molecular Neurobiology, 2012, 46, 495-512.	1.9	28
38	Association between dopamine beta hydroxylase rs5320 polymorphism and smoking behaviour in elderly Japanese. Journal of Human Genetics, 2012, 57, 385-390.	1.1	16

#	Article	IF	Citations
39	Transcranial near-infrared laser therapy applied to promote clinical recovery in acute and chronic neurodegenerative diseases. Expert Review of Medical Devices, 2012, 9, 71-83.	1.4	53
40	25-Hydroxyvitamin D Depletion Does Not Exacerbate MPTP-Induced Dopamine Neuron Damage in Mice. PLoS ONE, 2012, 7, e39227.	1.1	13
41	HLA-DRB1 Alleles Are Associated with the Susceptibility to Sporadic Parkinson's Disease in Chinese Han Population. PLoS ONE, 2012, 7, e48594.	1.1	30
42	Gene Therapy for the Treatment of Parkinson's Disease: The Nature of the Biologics Expands the Future Indications. Pharmaceuticals, 2012, 5, 553-590.	1.7	7
43	LINE-1 DNA Methylation, Smoking and Risk of Parkinson's Disease. Journal of Parkinson's Disease, 2012, 2, 303-308.	1.5	19
44	A Meta-Analysis of Tea Drinking and Risk of Parkinson's Disease. Scientific World Journal, The, 2012, 2012, 1-6.	0.8	38
45	Medaka Fish Parkinson's Disease Model. Experimental Neurobiology, 2012, 21, 94-100.	0.7	18
46	Nicotine as a potential neuroprotective agent for Parkinson's disease. Movement Disorders, 2012, 27, 947-957.	2.2	193
47	PINK1 Overexpression Protects Against C2-ceramide-Induced CAD Cell Death Through the PI3K/AKT Pathway. Journal of Molecular Neuroscience, 2012, 47, 582-594.	1.1	24
48	Parkinsonism secondary to subdural haematoma. Neurosurgical Review, 2012, 35, 457-461.	1.2	14
49	A scaffold hopping approach to identify novel monoamine oxidase B inhibitors. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 1380-1383.	1.0	32
50	Age and Sex Variation in Prevalence of Chronic Medical Conditions in Older Residents of <scp>U.S</scp> . Nursing Homes. Journal of the American Geriatrics Society, 2012, 60, 756-764.	1.3	95
51	Characterization of human cytochrome P450 induction by pesticides. Toxicology, 2012, 294, 17-26.	2.0	74
52	Paraquat and Parkinson's disease: An overview of the epidemiology and a review of two recent studies. Regulatory Toxicology and Pharmacology, 2012, 62, 385-392.	1.3	31
53	The role of $\hat{I}_{\pm}$ -synuclein in neurodegeneration $\hat{a} \in$ " An update. Translational Neuroscience, 2012, 3, .	0.7	16
54	Synaptic Protein Alterations in Parkinson's Disease. Molecular Neurobiology, 2012, 45, 126-143.	1.9	27
56	Parkinson's disease: considerations for dental hygienists. International Journal of Dental Hygiene, 2013, 11, 15-21.	0.8	17
57	Parkinson's disease and pesticide exposure – a new assessment. Critical Reviews in Toxicology, 2013, 43, 515-534.	1.9	71

		CITATION REPORT		
#	Article		IF	CITATIONS
58	Cell based therapy in Parkinsonism. Translational Neurodegeneration, 2013, 2, 13.		3.6	5
59	Morbidities in rapid eye movement sleep behavior disorder. Sleep Medicine, 2013, 14,	782-787.	0.8	16
60	Pharmacokinetic, neurochemical, stereological and neuropathological studies on the p effects of paraquat in the substantia nigra pars compacta and striatum of male C57BL NeuroToxicology, 2013, 37, 1-14.		1.4	43
61	Dermal Exposure Associated with Occupational End Use of Pesticides and the Role of Measures. Safety and Health at Work, 2013, 4, 136-141.	Protective	0.3	115
62	Parkinson Disease Protein DJ-1 Binds Metals and Protects against Metal-induced Cytot of Biological Chemistry, 2013, 288, 22809-22820.	coxicity. Journal	1.6	74
63	Microglia express distinct M1 and M2 phenotypic markers in the postnatal and adult c system in male and female mice. Journal of Neuroscience Research, 2013, 91, 1143-11	entral nervous 51.	1.3	287
64	Good and bad sides of diet in Parkinson's disease. Nutrition, 2013, 29, 474-475.		1.1	7
65	Parkinson's disease and history of outdoor occupation. Parkinsonism and Related Disc 1164-1166.	orders, 2013, 19,	1.1	10
66	Pesticide-Induced Gene Mutations and Parkinson Disease Risk: A Meta-Analysis. Genet Molecular Biomarkers, 2013, 17, 826-832.	ic Testing and	0.3	20
67	Paths from Pesticides to Parkinson's. Science, 2013, 341, 722-723.		6.0	120
68	Dietary and lifestyle variables in relation to incidence of Parkinson's disease in Gre Journal of Epidemiology, 2013, 28, 67-77.	ece. European	2.5	110
69	Gene–environment interactions in Parkinson's disease: Specific evidence in humans models. Neurobiology of Disease, 2013, 57, 38-46.	and mammalian	2.1	158
70	Glutamate in Parkinson's disease: Role of antiglutamatergic drugs. Basal Ganglia, 2013	3, 3, 147-157.	0.3	20
71	Solvents and Parkinson disease: A systematic review of toxicological and epidemiologi Toxicology and Applied Pharmacology, 2013, 266, 345-355.	cal evidence.	1.3	60
72	Alcohol use disorders and risk of Parkinson's disease: findings from a Swedish nati 1972–2008. BMC Neurology, 2013, 13, 190.	onal cohort study	0.8	39
73	The Rotterdam Study: 2014 objectives and design update. European Journal of Epiden 889-926.	niology, 2013, 28,	2.5	282
74	The Relation of Uric Acid to Brain Atrophy and Cognition: The Rotterdam Scan Study. Neuroepidemiology, 2013, 41, 29-34.		1.1	64
75	Functional paraoxonase 1 variants modify the risk of Parkinson's disease due to organ exposure. Environment International, 2013, 56, 42-47.	ophosphate	4.8	50

#	ARTICLE	IF	CITATIONS
76 77	User-centred design of a mobile self-management solution for Parkinson's disease. , 2013, , . The role of pesticide exposure in the genesis of Parkinson's disease: Epidemiological studies and experimental data. Toxicology, 2013, 307, 24-34.	2.0	28 57
78	LPS-induced oxidative stress and inflammatory reaction in the rat striatum. Pharmacological Reports, 2013, 65, 863-869.	1.5	65
79	Cross-species approaches to pathological gambling: A review targeting sex differences, adolescent vulnerability and ecological validity of research tools. Neuroscience and Biobehavioral Reviews, 2013, 37, 2454-2471.	2.9	44
80	The interplay between environmental and genetic factors in Parkinson's disease susceptibility: The evidence for pesticides. Toxicology, 2013, 307, 17-23.	2.0	95
81	Pesticides, Microglial NOX2, and Parkinson's Disease. Journal of Biochemical and Molecular Toxicology, 2013, 27, 137-149.	1.4	50
82	Gender differences in brain susceptibility to oxidative stress are mediated by levels of paraoxonase-2 expression. Free Radical Biology and Medicine, 2013, 58, 98-108.	1.3	92
83	Neurochemical profiling of dopaminergic neurons in the forebrain of a cichlid fish, Astatotilapia burtoni. Journal of Chemical Neuroanatomy, 2013, 47, 106-115.	1.0	26
84	Parkinson's disease in the nuclear age of neuroinflammation. Trends in Molecular Medicine, 2013, 19, 187-196.	3.5	101
85	Progress in gene therapy for neurological disorders. Nature Reviews Neurology, 2013, 9, 277-291.	4.9	202
86	Psoriasis is associated with an increased risk of parkinsonism: A population-based 5-year follow-up study. Journal of the American Academy of Dermatology, 2013, 68, 992-999.	0.6	33
87	Nicotine from edible <i>Solanaceae</i> and risk of Parkinson disease. Annals of Neurology, 2013, 74, 472-477.	2.8	58
88	Rasagiline in Parkinson's disease: A review based on meta-analysis of clinical data. Pharmacological Research, 2013, 74, 78-86.	3.1	28
89	Rifampicin and Parkinson's disease. Neurological Sciences, 2013, 34, 137-141.	0.9	51
90	Nicotine-Induced Structural Plasticity in Mesencephalic Dopaminergic Neurons Is Mediated by Dopamine D3 Receptors and Akt-mTORC1 Signaling. Molecular Pharmacology, 2013, 83, 1176-1189.	1.0	61
91	Statin use and risk of Parkinson's disease: a meta-analysis of observational studies. Journal of Neurology, 2013, 260, 158-165.	1.8	55
92	Risk factors for dementia with Lewy bodies. Neurology, 2013, 81, 833-840.	1.5	136
93	Association Between Early-Onset Parkinson Disease and 22q11.2 Deletion Syndrome. JAMA Neurology, 2013, 70, 1359.	4.5	132

	CHATION R		
# 94	ARTICLE Parkinson's disease: Evidence for environmental risk factors. Movement Disorders, 2013, 28, 8-13.	IF 2.2	Citations
95	The hallmarks of <scp>P</scp> arkinson's disease. FEBS Journal, 2013, 280, 5981-5993.	2.2	214
96	Developmental neuroplasticity and the origin of neurodegenerative diseases. World Journal of Biological Psychiatry, 2016, 17, 1-13.	1.3	28
97	Mapping and kinetics of microglia/neuron cell-to-cell contacts in the 6-OHDA murine model of Parkinson's disease. Clia, 2013, 61, 1645-1658.	2.5	35
98	Significantly higher frequency of <i><scp>H</scp>elicobacter suis</i> in patients with idiopathic parkinsonism than in control patients. Alimentary Pharmacology and Therapeutics, 2013, 38, 1347-1353.	1.9	54
99	Ayurvedic Constitution ( <i>Prakruti</i> ) Identifies Risk Factor of Developing Parkinson's Disease. Journal of Alternative and Complementary Medicine, 2013, 19, 644-649.	2.1	11
100	Acetaldehyde and parkinsonism: role of CYP450 2E1. Frontiers in Behavioral Neuroscience, 2013, 7, 71.	1.0	24
101	Prevalence of Parkinson's disease and other types of Parkinsonism in Al Kharga district, Egypt. Neuropsychiatric Disease and Treatment, 2013, 9, 1821.	1.0	17
102	Technical aids and housing adaptations among very old people with self-reported Parkinson's disease compared to matched controls. Journal of Parkinsonism and Restless Legs Syndrome, 2013, , 41.	0.8	3
103	Human α4β2 Nicotinic Acetylcholine Receptor as a Novel Target of Oligomeric α-Synuclein. PLoS ONE, 2013, 8, e55886.	1.1	12
104	Phenotypic Characterization of Retinoic Acid Differentiated SH-SY5Y Cells by Transcriptional Profiling. PLoS ONE, 2013, 8, e63862.	1.1	185
105	Alterations in Energy Metabolism, Neuroprotection and Visual Signal Transduction in the Retina of Parkinsonian, MPTP-Treated Monkeys. PLoS ONE, 2013, 8, e74439.	1.1	30
106	Interleukin-1β and tumor necrosis factor-α: reliable targets for protective therapies in Parkinson's Disease?. Frontiers in Cellular Neuroscience, 2013, 7, 53.	1.8	123
107	Rehabilitation and Parkinson's Disease 2013. Parkinson's Disease, 2013, 2013, 1-1.	0.6	3
108	Housing and Health: Very Old People with Self-Reported Parkinson's Disease versus Controls. Parkinson's Disease, 2013, 2013, 1-8.	0.6	14
109	Caffeine Interaction with Glutamate Receptor Gene GRIN2A: Parkinson's Disease in Swedish Population. PLoS ONE, 2014, 9, e99294.	1.1	28
110	Activation of MAPK and FoxO by Manganese (Mn) in Rat Neonatal Primary Astrocyte Cultures. PLoS ONE, 2014, 9, e94753.	1.1	40
111	miR-16-1 Promotes the Aberrant <i>α</i> -Synuclein Accumulation in Parkinson Disease via Targeting Heat Shock Protein 70. Scientific World Journal, The, 2014, 2014, 1-8.	0.8	51

ATION REDO

#	Article	IF	CITATIONS
112	TRYCAT Pathways Link Peripheral Inflammation, Nicotine, Somatization and Depression in the Etiology and Course of Parkinson's Disease. CNS and Neurological Disorders - Drug Targets, 2014, 13, 137-149.	0.8	29
113	Targeted Suppression of Chaperone-Mediated Autophagy by miR-320a Promotes α-Synuclein Aggregation. International Journal of Molecular Sciences, 2014, 15, 15845-15857.	1.8	42
114	Examining the Relationship between Head Trauma and Neurodegenerative Disease: A Review of Epidemiology, Pathology and Neuroimaging Techniques. , 2014, 04, .		32
115	Multiple System Atrophy: Genetic or Epigenetic?. Experimental Neurobiology, 2014, 23, 277-291.	0.7	28
116	Exploring the Pathogenetic Mechanisms underlying Parkinson's Disease in Medaka Fish. Journal of Parkinson's Disease, 2014, 4, 301-310.	1.5	15
117	Validity of geographically modeled environmental exposure estimates. Critical Reviews in Toxicology, 2014, 44, 450-466.	1.9	25
118	Association of NQO1 and TNF polymorphisms with Parkinson's disease: A meta-analysis of 15 genetic association studies. Biomedical Reports, 2014, 2, 713-718.	0.9	13
119	Pharmacological Chaperone Design for Reducing Risk Factor of Parkinson's Disease from Traditional Chinese Medicine. Evidence-based Complementary and Alternative Medicine, 2014, 2014, 1-12.	0.5	21
120	Polymorphisms of DRD2 and DRD3 genes and Parkinson's disease: A meta-analysis. Biomedical Reports, 2014, 2, 275-281.	0.9	27
121	Dietary fat and antioxidant vitamin intake in patients of neurodegenerative disease in a rural region of Jalisco, Mexico. Nutritional Neuroscience, 2014, 17, 260-267.	1.5	8
122	Profile of levodopa-induced dyskinesia in patients of Parkinson's disease: a record based study. Neurological Research, 2014, 36, 841-846.	0.6	1
123	Multiple-time-scale framework for understanding the progression of Parkinson's disease. Physical Review E, 2014, 90, 062709.	0.8	13
124	Rotigotine transdermal system: developing continuous dopaminergic delivery to treat Parkinson's disease and restless legs syndrome. Annals of the New York Academy of Sciences, 2014, 1329, 45-66.	1.8	27
126	Gut feelings about smoking and coffee in Parkinson's disease. Movement Disorders, 2014, 29, 976-979.	2.2	91
127	Epidemiological Studies of Parkinsonism in Welders. Issues in Toxicology, 2014, , 513-523.	0.2	0
128	Do genetic factors protect against Parkinson's disease? What I can learn from my healthy grandma. Medical Hypotheses, 2014, 83, 637-639.	0.8	2
129	Morbidity in early Parkinson's disease and prior to diagnosis. Brain and Behavior, 2014, 4, 446-452.	1.0	15
130	Job Exposure Matrix (JEM)-Derived Estimates of Lifetime Occupational Pesticide Exposure and the Risk of Parkinson's Disease. Archives of Environmental and Occupational Health, 2014, 69, 241-251.	0.7	35

#	Article	IF	CITATIONS
131	Meta-analyses of seven GICYF2 polymorphisms with Parkinson's disease. Biomedical Reports, 2014, 2, 886-892.	0.9	9
132	Tai Chi for Improvement of Motor Function, Balance and Gait in Parkinson's Disease: A Systematic Review and Meta-Analysis. PLoS ONE, 2014, 9, e102942.	1.1	102
133	Neuropathology of Parkinson's Disease. , 2014, , 25-74.		12
134	EPO-Dependent Activation of PI3K/Akt/FoxO3a Signalling Mediates Neuroprotection in In Vitro and In Vivo Models of Parkinson's Disease. Journal of Molecular Neuroscience, 2014, 53, 117-124.	1.1	71
135	Cellular impact of combinations of endosulfan, atrazine, and chlorpyrifos on human primary hepatocytes and HepaRG cells after short and chronic exposures. Cell Biology and Toxicology, 2014, 30, 17-29.	2.4	33
136	Evidence for modest familial co-aggregation between dementia and parkinsonism. European Journal of Epidemiology, 2014, 29, 49-56.	2.5	6
137	Neurodegeneration in Parkinson's Disease: Interactions of Oxidative Stress, Tryptophan Catabolites and Depression with Mitochondria and Sirtuins. Molecular Neurobiology, 2014, 49, 771-783.	1.9	72
138	Alcohol intake and risk of Parkinson's disease: A metaâ€∎nalysis of observational studies. Movement Disorders, 2014, 29, 819-822.	2.2	75
139	miR-126 contributes to Parkinson's disease by dysregulating the insulin-like growth factor/phosphoinositide 3-kinase signaling. Neurobiology of Aging, 2014, 35, 1712-1721.	1.5	120
140	Viral Vector-Based Models of Parkinson's Disease. Current Topics in Behavioral Neurosciences, 2014, 22, 271-301.	0.8	35
141	Paraoxonase-2 (PON2) in brain and its potential role in neuroprotection. NeuroToxicology, 2014, 43, 3-9.	1.4	68
142	Metabolism and functions of copper in brain. Progress in Neurobiology, 2014, 116, 33-57.	2.8	351
143	Neuropathology of cigarette smoking. Acta Neuropathologica, 2014, 127, 53-69.	3.9	41
144	Parkinson's Disease and Cancer: A Register-based Family Study. American Journal of Epidemiology, 2014, 179, 85-94.	1.6	58
145	Parkinson's disease and Alzheimer disease: environmental risk factors. NeurologÃa (English Edition), 2014, 29, 541-549.	0.2	51
146	Later age at onset in Parkinson's disease over twenty years in an Italian tertiary clinic. Parkinsonism and Related Disorders, 2014, 20, 1181-1185.	1.1	3
147	Nuclear Medicine Imaging and Therapy: Gender Biases in Disease. Seminars in Nuclear Medicine, 2014, 44, 413-422.	2.5	2
148	αâ€synucleinâ€induced mitochondrial dysfunction in isolated preparation and intact cells: Implications in the pathogenesis of Parkinson's disease. Journal of Neurochemistry, 2014, 131, 868-877.	2.1	45

#	Article	IF	CITATIONS
149	Osteoporosis in neurodegeneration. Journal of Trace Elements in Medicine and Biology, 2014, 28, 418-421.	1.5	39
150	Modulation of cAMP-Specific PDE without Emetogenic Activity: New Sulfide-Like PDE7 Inhibitors. Journal of Medicinal Chemistry, 2014, 57, 8590-8607.	2.9	24
151	Volumetric analysis of the subthalamic and red nuclei based on magnetic resonance imaging in patients with Parkinson's disease. International Journal of Neuroscience, 2014, 124, 291-295.	0.8	14
152	The significance of <i>GBA</i> for Parkinson's disease. Journal of Inherited Metabolic Disease, 2014, 37, 643-648.	1.7	36
153	Reduced risk of Parkinson's disease associated with lower body mass index and heavy leisure-time physical activity. European Journal of Epidemiology, 2014, 29, 285-292.	2.5	60
154	Analysis of mutations in patients with suspected autosomal dominant forms of Parkinson's disease. Molecular Genetics, Microbiology and Virology, 2014, 29, 1-3.	0.0	5
155	Absence of P-Glycoprotein Transport in the Pharmacokinetics and Toxicity of the Herbicide Paraquat. Journal of Pharmacology and Experimental Therapeutics, 2014, 348, 336-345.	1.3	17
156	BST1 rs11724635 interacts with environmental factors to increase the risk of Parkinson's disease in a Taiwanese population. Parkinsonism and Related Disorders, 2014, 20, 280-283.	1.1	28
157	Expression analysis of genes of ubiquitin-proteasome protein degradation system in MPTP-induced mice models of early stages of Parkinson's disease. Doklady Biochemistry and Biophysics, 2014, 456, 116-118.	0.3	18
158	Psychometric properties of four fear of falling rating scales in people with Parkinson's disease. BMC Geriatrics, 2014, 14, 66.	1.1	51
159	CHRNB3 c57A>G functional promoter change affects Parkinson's disease and smoking. Neurobiology of Aging, 2014, 35, 2179.e1-2179.e6.	1.5	10
160	Evaluation of a screening questionnaire for Parkinson's disease in a Chinese population. Journal of Clinical Neuroscience, 2014, 21, 278-281.	0.8	6
161	Enfermedad de Parkinson y enfermedad de Alzheimer: factores de riesgo ambientales. NeurologÃa, 2014, 29, 541-549.	0.3	85
162	Dairy foods intake and risk of Parkinson's disease: a dose–response meta-analysis of prospective cohort studies. European Journal of Epidemiology, 2014, 29, 613-619.	2.5	91
163	The clearance of misfolded proteins in neurodegenerative diseases by zinc metalloproteases: An inorganic perspective. Coordination Chemistry Reviews, 2014, 260, 139-155.	9.5	26
164	A Validation Study of Administrative Data Algorithms to Identify Patients with Parkinsonism with Prevalence and Incidence Trends. Neuroepidemiology, 2014, 43, 28-37.	1.1	64
165	Familial Coaggregation of Alzheimer's Disease and Parkinson's Disease: Systematic Review and Meta-Analysis. Neuroepidemiology, 2014, 42, 69-80.	1.1	9
166	Combined Nurr1 and Foxa2 roles in the therapy of Parkinson's disease. EMBO Molecular Medicine, 2015, 7, 510-525.	3.3	75

#	Article	IF	CITATIONS
167	Genetic association of RIT2 rs12456492 polymorphism and Parkinson's disease susceptibility in Asian populations: a meta-analysis. Scientific Reports, 2015, 5, 13805.	1.6	21
168	Barriers and Facilitators for Participation inÂPeople with Parkinson's Disease. Journal of Parkinson's Disease, 2015, 5, 983-992.	1.5	21
169	Heat shock protein 70 induction by glutamine increases the $\hat{I}\pm$ -synuclein degradation in SH-SY5Y neuroblastoma cells. Molecular Medicine Reports, 2015, 12, 5524-5530.	1.1	11
170	Linking Smoking, Coffee, Urate, and Parkinson's Disease – A Role for Gut Microbiota?. Journal of Parkinson's Disease, 2015, 5, 255-262.	1.5	59
171	The Epidemiology of Neuromuscular Disorders: A Comprehensive Overview of the Literature. Journal of Neuromuscular Diseases, 2015, 2, 73-85.	1.1	200
172	High rates of parkinsonism in adults with autism. Journal of Neurodevelopmental Disorders, 2015, 7, 29.	1.5	63
173	spargel, the PGC-11 $\pm$ homologue, in models of Parkinson disease in Drosophila melanogaster. BMC Neuroscience, 2015, 16, 70.	0.8	21
174	Vagotomy and subsequent risk of <scp>P</scp> arkinson's disease. Annals of Neurology, 2015, 78, 522-529.	2.8	625
175	BEWARE: Body awareness training in the treatment of wearing-off related anxiety in patients with Parkinson's disease: study protocol for a randomized controlled trial. Trials, 2015, 16, 283.	0.7	7
176	Neuroinflammation in Parkinson's disease and its potential as therapeutic target. Translational Neurodegeneration, 2015, 4, 19.	3.6	608
178	Psychometric properties of the Satisfaction With Life Scale in Parkinson's disease. Acta Neurologica Scandinavica, 2015, 132, 164-170.	1.0	21
179	In vitro evaluation of a closed-loop feedback system for dopamine concentration control. Research on Biomedical Engineering, 2015, 31, 26-32.	1.5	3
180	Association of Parkinson's Disease and Its Subtypes with Agricultural Pesticide Exposures in Men: A Case–Control Study in France. Environmental Health Perspectives, 2015, 123, 1123-1129.	2.8	72
181	Brain-gut-microbiota axis in Parkinson's disease. World Journal of Gastroenterology, 2015, 21, 10609.	1.4	438
182	Occupational exposures and parkinsonism. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2015, 131, 225-239.	1.0	18
183	Medium-to-high prevalence of screening-detected parkinsonism in the urban area of Tehran, Iran: data from a community-based door-to-door study. Neuropsychiatric Disease and Treatment, 2015, 11, 321.	1.0	15
184	Baseline Plasma C-Reactive Protein Concentrations and Motor Prognosis in Parkinson Disease. PLoS ONE, 2015, 10, e0136722.	1.1	33
185	Depression and subsequent risk of Parkinson disease. Neurology, 2015, 84, 2422-2429.	1.5	151

#	Article	IF	CITATIONS
186	Candidate genes for Parkinson disease: Lessons from pathogenesis. Clinica Chimica Acta, 2015, 449, 68-76.	0.5	25
187	Midbrain dopamine neurons in Parkinson׳s disease exhibit a dysregulated miRNA and target-gene network. Brain Research, 2015, 1618, 111-121.	1.1	88
188	Coffee, Genetic Variants, and Parkinson's Disease: Gene–Environment Interactions. Journal of Caffeine Research, 2015, 5, 3-10.	1.0	7
189	Non-coding RNA in neural function, disease, and aging. Frontiers in Genetics, 2015, 6, 87.	1.1	78
190	Occupational exposures and Parkinson's disease mortality in a prospective Dutch cohort. Occupational and Environmental Medicine, 2015, 72, 448-455.	1.3	48
191	SNCA rs3822086 C>T Polymorphism Increases the Susceptibility to Parkinson's Disease in a Chinese Han Population. Genetic Testing and Molecular Biomarkers, 2015, 19, 481-487.	0.3	3
192	Parkinson's disease research in a prospective cohort in China. Parkinsonism and Related Disorders, 2015, 21, 1200-1204.	1.1	27
193	Prevalence of Parkinsonism and Parkinson's disease in Qena governorate/Egypt: a cross-sectional community-based survey. Neurological Research, 2015, 37, 607-618.	0.6	20
194	Macronutrients intake and risk of <scp>P</scp> arkinson's disease: A metaâ€analysis. Geriatrics and Gerontology International, 2015, 15, 606-616.	0.7	30
195	Systematic review and meta-analysis of hydrocarbon exposure and the risk of Parkinson's disease. Parkinsonism and Related Disorders, 2015, 21, 243-248.	1.1	11
196	Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes. Parkinsonism and Related Disorders, 2015, 21, 231-235.	1.1	118
197	A Recurrent Mutation in PARK2 Is Associated with Familial Lung Cancer. American Journal of Human Genetics, 2015, 96, 301-308.	2.6	61
198	Effects of Omega-3 on Neurodegenerative Diseases and Stroke. , 2015, , 187-201.		0
199	Depressive symptoms in Parkinson's disease are related to decreased hippocampus and amygdala volume. Movement Disorders, 2015, 30, 245-252.	2.2	118
200	Parkinson's disease as a result of aging. Aging Cell, 2015, 14, 293-308.	3.0	165
201	Pathologic and therapeutic implications for the cell biology of parkin. Molecular and Cellular Neurosciences, 2015, 66, 62-71.	1.0	27
202	Prospective study on the components of metabolic syndrome and the incidence of Parkinson's disease. Parkinsonism and Related Disorders, 2015, 21, 1148-1155.	1.1	52
203	Translational research for Parkinson׳s disease: The value of pre-clinical primate models. European Journal of Pharmacology, 2015, 759, 118-126.	1.7	11

#	Article	IF	Citations
204	Clinically meaningful parameters of progression and long-term outcome of Parkinson disease: An international consensus statement. Parkinsonism and Related Disorders, 2015, 21, 675-682.	1.1	22
205	Inverse association between yerba mate consumption and idiopathic Parkinson's disease. A case–control study. Journal of the Neurological Sciences, 2015, 356, 163-167.	0.3	17
206	Epidemiology and Environmental Risk Factors Associated with Vestibular Schwannoma. World Neurosurgery, 2015, 84, 1674-1680.	0.7	30
207	Quantification of Diabetes Comorbidity Risks across Life Using Nation-Wide Big Claims Data. PLoS Computational Biology, 2015, 11, e1004125.	1.5	59
208	Tea Polyphenols in Parkinson's Disease. Advances in Experimental Medicine and Biology, 2015, 863, 117-137.	0.8	67
209	Validation and reliability of a modified sphygmomanometer for the assessment of handgrip strength in Parkinson´s disease. Brazilian Journal of Physical Therapy, 2015, 19, 137-145.	1.1	16
210	Alpha7 nicotinic receptors as therapeutic targets for Parkinson's disease. Biochemical Pharmacology, 2015, 97, 399-407.	2.0	93
211	Best practice in placement of percutaneous endoscopic gastrostomy with jejunal extension tube for continuous infusion of levodopa carbidopa intestinal gel in the treatment of selected patients with Parkinson's disease in the Nordic region. Scandinavian Journal of Gastroenterology, 2015, 50, 1500-1507.	0.6	15
212	Association Between Parkinson Disease and Risk of Cancer in Taiwan. JAMA Oncology, 2015, 1, 633.	3.4	66
213	Epidemiology of early-onset Parkinson's disease in Finland. Parkinsonism and Related Disorders, 2015, 21, 938-942.	1.1	24
214	Environmental Exposures and Risks for Parkinson's Disease. , 2015, , 253-265.		1
215	Interaction of methamphetamine abuse, tobacco abuse, and gender in the brain. American Journal of Drug and Alcohol Abuse, 2015, 41, 269-271.	1.1	2
216	A populationâ€based study on combined markers for early Parkinson's disease. Movement Disorders, 2015, 30, 531-537.	2.2	20
217	Support supplied by Parkinson's disease specialist nurses to Parkinson's disease patients and their spouses. Applied Nursing Research, 2015, 28, 86-91.	1.0	39
218	Head injury, potential interaction with genes, and risk for Parkinson's disease. Parkinsonism and Related Disorders, 2015, 21, 292-296.	1.1	27
219	Environmental pollutants as risk factors for neurodegenerative disorders: Alzheimer and Parkinson diseases. Frontiers in Cellular Neuroscience, 2015, 9, 124.	1.8	439
220	Longitudinal follow-up and characterization of a robust rat model for Parkinson's disease based on overexpression of alpha-synuclein with adeno-associated viral vectors. Neurobiology of Aging, 2015, 36, 1543-1558.	1.5	75
221	Angiotensin II Triggers Apoptosis Via Enhancement of NADPH Oxidase-Dependent Oxidative Stress in a Dopaminergic Neuronal Cell Line. Neurochemical Research, 2015, 40, 854-863.	1.6	26

#	Article	IF	Citations
	Molecular chaperones and neuronal proteostasis. Seminars in Cell and Developmental Biology, 2015,		
222	40, 142-152.	2.3	81
223	Occupational exposure to solvents, metals and welding fumes and risk of Parkinson's disease. Parkinsonism and Related Disorders, 2015, 21, 635-639.	1.1	20
224	Clobal market for implanted neuroprostheses. , 2015, , 383-394.		9
225	Chronic Obstructive Pulmonary Disease, Hospital Visits, and Comorbidities. Journal of Aging and Health, 2015, 27, 480-499.	0.9	24
226	Nicotine and Nicotinic Receptor Drugs. International Review of Neurobiology, 2015, 124, 247-271.	0.9	59
227	Association between cigarette smoking and Parkinson's disease: A meta-analysis. Archives of Gerontology and Geriatrics, 2015, 61, 510-516.	1.4	119
228	Biomarker sources for Parkinson's disease: Time to shed tears?. Basal Ganglia, 2015, 5, 63-69.	0.3	21
229	Diametrical diseases reflect evolutionary-genetic tradeoffs. Evolution, Medicine and Public Health, 2015, 2015, 216-253.	1.1	49
230	Combined therapy of Di-Huang-Yi-Zhi with Donepezil in patients with Parkinson's disease dementia. Neuroscience Letters, 2015, 606, 13-17.	1.0	15
231	Contributo da avaliação psicológica no exame clÃnico de condutores com doença neurológica e psiquiátrica: revisão teórica. Revista Portuguesa De Saude Publica, 2015, 33, 57-70.	0.3	1
232	Exploring the Role of Autophagy in the Pathogenesis of Rotenone-induced Toxicity. Current Topics in Neurotoxicity, 2015, , 225-245.	0.4	0
233	DNA methylation levels of α-synuclein intron 1 in the aging brain. Neurobiology of Aging, 2015, 36, 3334.e7-3334.e11.	1.5	23
234	Identification of dopaminergic neurons of the substantia nigra pars compacta as a target of manganese accumulation. Metallomics, 2015, 7, 748-755.	1.0	38
235	P-Glycoprotein Transport of Neurotoxic Pesticides. Journal of Pharmacology and Experimental Therapeutics, 2015, 355, 99-107.	1.3	22
236	Selective damage to dopaminergic transporters following exposure to the brominated flame retardant, HBCDD. Neurotoxicology and Teratology, 2015, 52, 162-169.	1.2	17
237	Preclinical Evidence for a Role of the Nicotinic Cholinergic System in Parkinson's Disease. Neuropsychology Review, 2015, 25, 371-383.	2.5	19
238	Increased risk of Parkinson's disease in cataract patients: A population-based cohort study. Parkinsonism and Related Disorders, 2015, 21, 68-71.	1.1	32
239	Methamphetamine/amphetamine abuse and risk of Parkinson's disease in Utah: A population-based assessment. Drug and Alcohol Dependence, 2015, 146, 30-38.	1.6	147

ARTICLE IF CITATIONS Burden of Neurological Disease., 2015, , 748-764. 240 0 Parkinson Disease and Other Synucleinopathies., 2015, , 281-302. 241 Gut microbiota are related to Parkinson's disease and clinical phenotype. Movement Disorders, 2015, 242 2.2 1,457 30, 350-358. Blood α-synuclein in agricultural pesticide handlers in central Washington State. Environmental 243 Research, 2015, 136, 75-81. The effect of cannabis on oxidative stress and neurodegeneration induced by intrastriatal rotenone 244 0.3 15 injection in rats. Comparative Clinical Pathology, 2015, 24, 359-378. An exome study of Parkinson's disease in Sardinia, a Mediterranean genetic isolate. Neurogenetics, 2015, 16, 55-64. Association between ubiquitin carboxy-terminal hydrolase-L1 S18Y variant and risk of Parkinson's 246 0.9 14 disease: the impact of ethnicity and onset age. Neurological Sciences, 2015, 36, 179-188. Parkinson's disease: chameleons and mimics. Practical Neurology, 2015, 15, 14-25. 247 The association between chronic obstructive pulmonary disease and Parkinson's disease: a nationwide 248 population-based retrospective cohort study. QJM - Monthly Journal of the Association of Physicians, 0.2 39 2015, 108, 39-45. Neuroprotective effects of aldehyde dehydrogenase 2 activation in rotenone-induced cellular and 249 animal models of parkinsonism. Experimental Neurology, 2015, 263, 244-253. The α7 nicotinic receptor agonist ABT-107 protects against nigrostriatal damage in rats with unilateral 250 2.0 50 6-hydroxydopamine lesions. Experimental Neurology, 2015, 263, 277-284. Informe de la FundaciÃ<sup>3</sup>n del Cerebro sobre el impacto social de la enfermedad de Parkinson en España. 0.3 29 NeurologÃa, 2016, 31, 401-413. Bipolar disorder, a precursor of Parkinson's disease?. Dementia E Neuropsychologia, 2016, 10, 361-364. 252 0.3 3 Drivers: A Biologically Contextualized, Cross-Inferential View of the Epidemiology of 1.2 Neurodegenerative Disorders. Journal of Alzheimer's Disease, 2016, 51, 1003-1022. 254 Heritability and Differential Susceptibility (to Mental Disorders)., 2016, , 305-314. 0 Pathophysiological Role of Neuroinflammation in Neurodegenerative Diseases and Psychiatric 188 Disorders. International Neurourology Journal, 2016, 20, S2-7. Hepcidin Plays a Key Role in 6-OHDA Induced Iron Overload and Apoptotic Cell Death in a Cell Culture 256 0.6 18 Model of Parkinson's Disease. Parkinson's Disease, 2016, 2016, 1-7. A Novel Homozygous p.L539F Mutation Identified in<i>PINK1</i>Gene in a Moroccan Patient with Parkinsonism. BioMed Research International, 2016, 2016, 1-5.

#	Article	IF	CITATIONS
258	Genetic Profile, Environmental Exposure, and Their Interaction in Parkinson's Disease. Parkinson's Disease, 2016, 2016, 1-9.	0.6	36
259	Parkinson's Disease and Homocysteine: A Community-Based Study in a Folate and Vitamin B12 Deficient Population. Parkinson's Disease, 2016, 2016, 1-6.	0.6	7
260	Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives. International Journal of Molecular Sciences, 2016, 17, 904.	1.8	146
261	Neurodegenerative Diseases: Might Citrus Flavonoids Play a Protective Role?. Molecules, 2016, 21, 1312.	1.7	97
262	Comparing the Incidence of Falls/Fractures in Parkinson's Disease Patients in the US Population. PLoS ONE, 2016, 11, e0161689.	1.1	59
263	Association between Parkinson's Disease and Cigarette Smoking, Rural Living, Well-Water Consumption, Farming and Pesticide Use: Systematic Review and Meta-Analysis. PLoS ONE, 2016, 11, e0151841.	1.1	149
264	Assessment of the Effects of MPTP and Paraquat on Dopaminergic Neurons and Microglia in the Substantia Nigra Pars Compacta of C57BL/6 Mice. PLoS ONE, 2016, 11, e0164094.	1.1	68
265	Effects of Exercise Therapy on Postural Instability in Parkinson Disease. Journal of Neurologic Physical Therapy, 2016, 40, 3-14.	0.7	71
266	Parkinson's Disease and Pesticides Exposure: New Findings From a Comprehensive Study in Nebraska, USA. Journal of Rural Health, 2016, 32, 303-313.	1.6	26
267	FPL tendon thickness, tremor and hand functions in Parkinson's disease. Open Medicine (Poland), 2016, 11, 16-20.	0.6	3
268	Grafted Neural Precursors Integrate Into Mouse Striatum, Differentiate and Promote Recovery of Function Through Release of Erythropoietin in MPTP-Treated Mice. ASN Neuro, 2016, 8, 175909141667614.	1.5	14
269	Cerebellar involvement in Parkinson's disease resting tremor. Cerebellum and Ataxias, 2016, 3, 13.	1.9	17
270	Influence of cigarette smoking on ALS outcome: a population-based study. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1229-1233.	0.9	37
271	Moist smokeless tobacco (Snus) use and risk of Parkinson's disease. International Journal of Epidemiology, 2017, 46, dyw294.	0.9	14
272	MiR-133b ameliorates axon degeneration induced by MPP+ via targeting RhoA. Neuroscience, 2016, 325, 39-49.	1.1	39
273	The social impact of Parkinson's disease in Spain: Report by the Spanish Foundation for the Brain. NeurologÃa (English Edition), 2016, 31, 401-413.	0.2	16
274	Statin use and risk of Parkinson's disease: A meta-analysis. Behavioural Brain Research, 2016, 309, 29-34.	1.2	42
275	Characterization of Upper-Limb Pathological Tremors: Application to Design of an Augmented Haptic Rehabilitation System. IEEE Journal on Selected Topics in Signal Processing, 2016, 10, 888-903.	7.3	30

#	Article	IF	CITATIONS
277	Associations between cancer and Parkinson's disease in U.S. elderly adults. International Journal of Epidemiology, 2016, 45, 741-751.	0.9	25
278	Developmental expression of paraoxonase 2. Chemico-Biological Interactions, 2016, 259, 168-174.	1.7	19
279	The epidemiology of Parkinson's disease: risk factors and prevention. Lancet Neurology, The, 2016, 15, 1257-1272.	4.9	1,233
280	The Implications of Parkinson's Disease for Women's Health. JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing, 2016, 45, 723-736.	0.2	2
281	Epidemiology of Parkinson's Disease: A Population-Based Study in Primary Care in Italy. Neuroepidemiology, 2016, 47, 38-45.	1.1	21
282	Evaluation of Speech Amplification Devices in Parkinson's Disease. American Journal of Speech-Language Pathology, 2016, 25, 29-45.	0.9	28
283	Immediate effects of perturbation treadmill training on gait and postural control in patients with Parkinson's disease. Gait and Posture, 2016, 50, 102-108.	0.6	37
284	The increased level of COX-dependent arachidonic acid metabolism in blood platelets from secondary progressive multiple sclerosis patients. Molecular and Cellular Biochemistry, 2016, 420, 85-94.	1.4	25
285	Advantages of nonhuman primates as preclinical models for evaluating stem cell-based therapies for Parkinson's disease. Stem Cell Research, 2016, 17, 352-366.	0.3	61
286	Appendectomy and risk of Parkinson's disease: A nationwide cohort study with more than 10 years of follow-up. Movement Disorders, 2016, 31, 1918-1922.	2.2	58
287	From the Cover: Arsenic Induces Accumulation of $\hat{I}\pm$ -Synuclein: Implications for Synucleinopathies and Neurodegeneration. Toxicological Sciences, 2016, 153, 271-281.	1.4	41
288	Uric Acid Induces Cognitive Dysfunction through Hippocampal Inflammation in Rodents and Humans. Journal of Neuroscience, 2016, 36, 10990-11005.	1.7	47
289	Parkinson disease male-to-female ratios increase with age: French nationwide study and meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 952-957.	0.9	169
290	Socioeconomic status in relation to Parkinson's disease risk and mortality. Medicine (United States), 2016, 95, e4337.	0.4	35
291	Comparison of Selegiline and Rasagiline Therapies in Parkinson Disease: A Real-life Study. Clinical Neuropharmacology, 2016, 39, 227-231.	0.2	24
293	Parkinson's disease and the Stroop color word test: processing speed and interference algorithms. Clinical Neuropsychologist, 2016, 30, 1104-1117.	1.5	23
294	Medication Therapy Management Service for Patients with Parkinson's Disease: A Before-and-After Study. Neurology and Therapy, 2016, 5, 85-99.	1.4	26
295	Paraoxonases-1, -2 and -3: What are their functions?. Chemico-Biological Interactions, 2016, 259, 51-62.	1.7	145

#	Article	IF	CITATIONS
296	Constipation and risk of Parkinson's disease: A Danish population-based cohort study. Parkinsonism and Related Disorders, 2016, 28, 18-22.	1.1	35
297	Adjustment disorder and risk of Parkinson's disease. European Journal of Neurology, 2016, 23, 751-756.	1.7	17
299	Association between two α-2-macroglobulin gene polymorphisms and Parkinson's disease: a meta-analysis. International Journal of Neuroscience, 2016, 126, 193-198.	0.8	9
300	Pluripotent stem cells in disease modelling and drug discovery. Nature Reviews Molecular Cell Biology, 2016, 17, 170-182.	16.1	488
301	Prevalence of parkinsonism estimated using the drug prescription archive: a possible method to estimate the prevalence of a chronic neurological disease?. Journal of Neural Transmission, 2016, 123, 415-420.	1.4	1
302	Environmental Risk Factors and Amyotrophic Lateral Sclerosis: An Umbrella Review and Critical Assessment of Current Evidence from Systematic Reviews and Meta-Analyses of Observational Studies. Neuroepidemiology, 2016, 46, 96-105.	1.1	74
303	Epidemiology of Parkinson's disease. Revue Neurologique, 2016, 172, 14-26.	0.6	292
304	Cytochrome P450 20A1 in zebrafish: Cloning, regulation and potential involvement in hyperactivity disorders. Toxicology and Applied Pharmacology, 2016, 296, 73-84.	1.3	20
305	Proton MR Spectroscopy for Monitoring Pathologic Changes in the Substantia Nigra and Globus Pallidus in Parkinson Disease. American Journal of Roentgenology, 2016, 206, 385-389.	1.0	12
306	Effects of sensory cueing in virtual motor rehabilitation. A review. Journal of Biomedical Informatics, 2016, 60, 49-57.	2.5	23
307	Effect of heat waves on morbidity and mortality due to Parkinson's disease in Madrid: A time-series analysis. Environment International, 2016, 89-90, 1-6.	4.8	37
308	Multifactorial theory applied to the neurotoxicity of paraquat and paraquat-induced mechanisms of developing Parkinson's disease. Laboratory Investigation, 2016, 96, 496-507.	1.7	73
309	Maladie de Parkinson et facteurs de risque professionnels et environnementauxÂ: enquête cas-témoins dans l'ouest algérien. Archives Des Maladies Professionnelles Et De L'Environnement, 2016, 77, 21-26.	0.1	3
310	Environmental risk factors and Parkinson's disease: An umbrella review of meta-analyses. Parkinsonism and Related Disorders, 2016, 23, 1-9.	1.1	307
311	Transcriptome profiling in Parkinson's leukocytes: from early diagnostics to neuroimmune therapeutic prospects. Current Opinion in Pharmacology, 2016, 26, 102-109.	1.7	12
312	InÂvivo characterization of a novel dopamine D3 receptor agonist to treat motor symptoms of Parkinson's disease. Neuropharmacology, 2016, 100, 106-115.	2.0	24
313	α-Synuclein Over-Expression Induces Increased Iron Accumulation and Redistribution in Iron-Exposed Neurons. Molecular Neurobiology, 2016, 53, 1925-1934.	1.9	60
314	Comparison of self and proxy ratings for voice handicap index and motor-related quality-of-life of individuals with Parkinson's disease. International Journal of Speech-Language Pathology, 2017, 19, 174-183.	0.6	24

ARTICLE IF CITATIONS # Investigation of Long Non-coding RNA Expression Profiles in the Substantia Nigra of Parkinson's 315 1.7 60 Disease. Cellular and Molecular Neurobiology, 2017, 37, 329-338. Context-sensitive network-based disease genetics prediction and its implications in drug discovery. 1.8 Bioinformatics, 2017, 33, 1031-1039. The SH-SY5Y cell line in Parkinson's disease research: a systematic review. Molecular 319 4.4 636 Neurodegeneration, 2017, 12, 10. Chronic Neurodegenerative Illnesses and Epilepsy in Danish Adventists and Baptists: A Nationwide Cohort Study. Journal of Alzheimer's Disease, 2017, 56, 1429-1435. Whole-exome sequencing of 228 patients with sporadic Parkinson's disease. Scientific Reports, 2017, 7, 321 1.6 27 41188. Modeling a Composite Score in Parkinson's Disease Using Item Response Theory. AAPS Journal, 2017, 19, 2.2 837-845 Acetyl-l-carnitine protects dopaminergic nigrostriatal pathway in 6-hydroxydopamine-induced model 323 2.5 33 of Parkinson's disease in the rat. Biomedicine and Pharmacotherapy, 2017, 89, 1-9. Coffee consumption is associated with DNA methylation levels of human blood. European Journal of 324 1.4 Human Genetics, 2017, 25, 608-616. Exposure to an enriched environment facilitates motor recovery and prevents short-term memory 325 impairment and reduction of striatal BDNF in a progressive pharmacological model of parkinsonism in 1.2 25 mice. Behavioural Brain Research, 2017, 328, 138-148. Core elements to understand and improve coping with Parkinson's disease in patients and family 1.5 carers: A focus group study. Journal of Advanced Nursing, 2017, 73, 2609-2621. Glaucoma correlates with increased risk of Parkinson's disease in the elderly: a national-based 327 0.9 30 cohort study in Taiwan. Current Medical Research and Opinion, 2017, 33, 1511-1516. Outdoor Ambient Air Pollution and Neurodegenerative Diseases: the Neuroinflammation Hypothesis. 3.2 142 Current Environmental Health Reports, 2017, 4, 166-179. Targeting urate to reduce oxidative stress in Parkinson disease. Experimental Neurology, 2017, 298, 329 2.0 103 210-224. Immunopathology of the Nervous System. Molecular and Integrative Toxicology, 2017, , 123-219. 331 Epigenetics in Parkinson's Disease. Advances in Experimental Medicine and Biology, 2017, 978, 363-390. 0.8 50 Tobacco Use, Oral Health, and Risk of Parkinson's Disease. American Journal of Epidemiology, 2017, 185, 538-545. Associations of Spatial Disparities of Alzheimer's Disease Mortality Rates with Soil Selenium and 333 Sulfur Concentrations and Four Common Risk Factors in the United States. Journal of Alzheimer's 1.2 12 Disease, 2017, 58, 897-907. The gut-brain axis in Parkinson's disease: Possibilities for food-based therapies. European Journal of 334 Pharmacology, 2017, 817, 86-95.

#	Article	IF	CITATIONS
335	Wnt/β-catenin signaling plays an essential role in α7 nicotinic receptor-mediated neuroprotection of dopaminergic neurons in a mouse Parkinson's disease model. Biochemical Pharmacology, 2017, 140, 115-123.	2.0	54
336	Counseling At-Risk Parkinson's Disease Cohorts: Integrating Emerging Evidence. Current Genetic Medicine Reports, 2017, 5, 100-107.	1.9	7
337	Recovery from experimental parkinsonism by intrastriatal application of erythropoietin or EPO-releasing neural precursors. Neuropharmacology, 2017, 119, 76-90.	2.0	17
338	Troxerutin exerts neuroprotection in 6-hydroxydopamine lesion rat model of Parkinson's disease: Possible involvement of PI3K/ERβ signaling. European Journal of Pharmacology, 2017, 801, 72-78.	1.7	39
339	Living near major roads and the incidence of dementia, Parkinson's disease, and multiple sclerosis: a population-based cohort study. Lancet, The, 2017, 389, 718-726.	6.3	567
340	The FBXO7 homologue nutcracker and binding partner PI31 in Drosophila melanogaster models of Parkinson's disease. Genome, 2017, 60, 46-54.	0.9	10
341	Epigenetic Biomarkers for Parkinson's Disease: From Diagnostics to Therapeutics. Journal of Parkinson's Disease, 2017, 7, 1-12.	1.5	43
342	Association of metabolic syndrome and change in Unified Parkinson's Disease Rating Scale scores. Neurology, 2017, 89, 1789-1794.	1.5	24
343	Development of a Thai Parkinson's Disease Screening Tool and the Prevalence of Parkinsonism and Parkinson's Disease, Based on a Community Survey in Bangkok. Neuroepidemiology, 2017, 49, 74-81.	1.1	6
344	Long-term effects of exercise and physical therapy in people with Parkinson disease. Nature Reviews Neurology, 2017, 13, 689-703.	4.9	318
345	Identification of key genes and pathways in Parkinson's disease through integrated analysis. Molecular Medicine Reports, 2017, 16, 3769-3776.	1.1	17
346	Glitazone use associated with reduced risk of Parkinson's disease. Movement Disorders, 2017, 32, 1594-1599.	2.2	90
347	Adverse effects produced by different drugs used in the treatment of Parkinson's disease: A mixed treatment comparison. CNS Neuroscience and Therapeutics, 2017, 23, 827-842.	1.9	39
348	Dietary antioxidants and risk of Parkinson's disease in two populationâ€based cohorts. Movement Disorders, 2017, 32, 1631-1636.	2.2	90
349	Dâ€512, a novel dopamine D <sub>2/3</sub> receptor agonist, demonstrates greater antiâ€Parkinsonian efficacy than ropinirole in Parkinsonian rats. British Journal of Pharmacology, 2017, 174, 3058-3071.	2.7	22
350	Environmental exposure to pesticides and the risk of Parkinson's disease in the Netherlands. Environment International, 2017, 107, 100-110.	4.8	121
351	Eradication of Helicobacter pylori infection might improve clinical status of patients with Parkinson's disease, especially on bradykinesia. Clinical Neurology and Neurosurgery, 2017, 160, 101-104.	0.6	34
352	Occurrence of spleen qi deficiency as defined by Chinese medicine in Parkinson disease. Journal of Traditional Chinese Medical Sciences, 2017, 4, 24-30.	0.1	3

#	Article	IF	CITATIONS
353	Disruption of Neurosynaptic Physiology and Neuron Network Dysfunction in Brain Disorders: an Environmental and Occupational Health Perspective. Activitas Nervosa Superior, 2017, 59, 61-77.	0.4	1
354	Perturbation During Treadmill Training Improves Dynamic Balance and Gait in Parkinson's Disease: A Single-Blind Randomized Controlled Pilot Trial. Neurorehabilitation and Neural Repair, 2017, 31, 758-768.	1.4	34
355	Echinacoside's nigrostriatal dopaminergic protection against 6â€OHDAâ€Induced endoplasmic reticulum stress through reducing the accumulation of Seipin. Journal of Cellular and Molecular Medicine, 2017, 21, 3761-3775.	1.6	28
356	Prevalence, Duration and Severity of Parkinson's Disease in Germany: A Combined Meta-Analysis from Literature Data and Outpatient Samples. European Neurology, 2017, 78, 128-136.	0.6	16
357	The aberrantly expressed long nonâ€coding <scp>RNA</scp> inÂthe substantia nigra and corpus striatum of Nrf2â€knockout mice. Journal of Neurochemistry, 2017, 143, 65-75.	2.1	17
358	Glutamine promotes Hsp70 and inhibits α-Synuclein accumulation in pheochromocytoma PC12 cells. Experimental and Therapeutic Medicine, 2017, 14, 1253-1259.	0.8	12
359	The anti-aging protein klotho alleviates injury of nigrostriatal dopaminergic pathway in 6-hydroxydopamine rat model of Parkinson's disease: Involvement of PKA/CaMKII/CREB signaling. Experimental Gerontology, 2017, 100, 70-76.	1.2	41
360	Organophosphate pesticides and PON1 L55M in Parkinson's disease progression. Environment International, 2017, 107, 75-81.	4.8	43
361	Expanding role of molecular chaperones in regulating α-synuclein misfolding; implications in Parkinson's disease. Cellular and Molecular Life Sciences, 2017, 74, 617-629.	2.4	23
362	Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease. European Journal of Neuroscience, 2017, 45, 20-33.	1.2	85
363	Gene therapy for Parkinson's disease: Disease modification by GDNF family of ligands. Neurobiology of Disease, 2017, 97, 179-188.	2.1	40
365	Neuroprotective Effects of Citrus Fruit-Derived Flavonoids, Nobiletin and Tangeretin in Alzheimer's and Parkinson's Disease. CNS and Neurological Disorders - Drug Targets, 2017, 16, 387-397.	0.8	101
366	Manganese Neurodegeneration. Advances in Neurotoxicology, 2017, 1, 157-183.	0.7	1
367	A multi-rate and auto-adjustable wavelet decomposition framework for pathological hand tremor extraction. , 2017, , .		2
368	Current Status, Gaps, and Weaknesses of the Mechanism of Selective Dopaminergic Toxicity of MPTP/MPP +. Advances in Molecular Toxicology, 2017, 11, 81-122.	0.4	6
369	Associations Between Lifestyle Factors And Parkinson's Disease In An Urban Sri Lankan Clinic Study. International Archive of Medicine, 2017, 10, .	1.2	7
370	Depression in Parkinson's Disease: The Contribution from Animal Studies. Parkinson's Disease, 2017, 2017, 1-8.	0.6	13
371	Specific Effects of Chronic Dietary Exposure to Chlorpyrifos on Brain Gene Expression—A Mouse Study. International Journal of Molecular Sciences, 2017, 18, 2467.	1.8	19

#	Article	IF	CITATIONS
372	Effects of Commonly Used Pesticides in China on the Mitochondria and Ubiquitin-Proteasome System in Parkinson's Disease. International Journal of Molecular Sciences, 2017, 18, 2507.	1.8	39
373	Hypermethylation of Synphilin-1, Alpha-Synuclein-Interacting Protein (SNCAIP) Gene in the Cerebral Cortex of Patients with Sporadic Parkinson's Disease. Brain Sciences, 2017, 7, 74.	1.1	9
374	A Life-Long Approach to Physical Activity for Brain Health. Frontiers in Aging Neuroscience, 2017, 9, 147.	1.7	52
375	Variants in SNCA Gene Are Associated with Parkinson's Disease Risk and Cognitive Symptoms in a Brazilian Sample. Frontiers in Aging Neuroscience, 2017, 9, 198.	1.7	40
376	Acute Neuromuscular Adaptations in the Postural Control of Patients with Parkinson's Disease after Perturbed Walking. Frontiers in Aging Neuroscience, 2017, 9, 316.	1.7	10
377	Metallothionein, Copper and Alpha-Synuclein in Alpha-Synucleinopathies. Frontiers in Neuroscience, 2017, 11, 114.	1.4	52
378	Protein Quality Control by Molecular Chaperones in Neurodegeneration. Frontiers in Neuroscience, 2017, 11, 185.	1.4	245
379	Phosphorylated <i>α</i> -Synuclein-Copper Complex Formation in the Pathogenesis of Parkinson's Disease. Parkinson's Disease, 2017, 2017, 1-9.	0.6	12
380	Body Posture, Postural Stability, and Metabolic Age in Patients with Parkinson's Disease. BioMed Research International, 2017, 2017, 1-9.	0.9	19
381	Catecholamines and Behavior â~†. , 2017, , .		0
382	Genetic Variants in SNCA and the Risk of Sporadic Parkinson's Disease and Clinical Outcomes: A		
	Review. Parkinson's Disease, 2017, 2017, 1-11.	0.6	32
383		0.6	32 68
383 384	Review. Parkinson's Disease, 2017, 2017, 1-11. The Role of CYP2E1 in the Drug Metabolism or Bioactivation in the Brain. Oxidative Medicine and		
	Review. Parkinson's Disease, 2017, 2017, 1-11. The Role of CYP2E1 in the Drug Metabolism or Bioactivation in the Brain. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-14. Complete Comparison Display (CCD) evaluation of ethanol extracts of Centella asiatica and Withania somnifera shows that they can non-synergistically ameliorate biochemical and behavioural damages	1.9	68
384	Review. Parkinson's Disease, 2017, 2017, 1-11. The Role of CYP2E1 in the Drug Metabolism or Bioactivation in the Brain. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-14. Complete Comparison Display (CCD) evaluation of ethanol extracts of Centella asiatica and Withania somnifera shows that they can non-synergistically ameliorate biochemical and behavioural damages in MPTP induced Parkinson's model of mice. PLoS ONE, 2017, 12, e0177254. The analysis of relationship between selected sociodemografic factors and disorders of speech	1.9 1.1	68 21
384 385	<ul> <li>Review. Parkinson's Disease, 2017, 2017, 1-11.</li> <li>The Role of CYP2E1 in the Drug Metabolism or Bioactivation in the Brain. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-14.</li> <li>Complete Comparison Display (CCD) evaluation of ethanol extracts of Centella asiatica and Withania somnifera shows that they can non-synergistically ameliorate biochemical and behavioural damages in MPTP induced Parkinson's model of mice. PLoS ONE, 2017, 12, e0177254.</li> <li>The analysis of relationship between selected sociodemografic factors and disorders of speech organs in Parkinson's patients. BMC Neurology, 2017, 17, 221.</li> <li>The PD COMM trial: a protocol for the process evaluation of a randomised trial assessing the</li> </ul>	1.9 1.1 0.8	68 21 1
384 385 386	Review. Parkinson's Disease, 2017, 2017, 1-11.         The Role of CYP2E1 in the Drug Metabolism or Bioactivation in the Brain. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-14.         Complete Comparison Display (CCD) evaluation of ethanol extracts of Centella asiatica and Withania somnifera shows that they can non-synergistically ameliorate biochemical and behavioural damages in MPTP induced Parkinson's model of mice. PLoS ONE, 2017, 12, e0177254.         The analysis of relationship between selected sociodemografic factors and disorders of speech organs in Parkinson's patients. BMC Neurology, 2017, 17, 221.         The PD COMM trial: a protocol for the process evaluation of a randomised trial assessing the effectiveness of two types of SLT for people with Parkinson's disease. Trials, 2017, 18, 397.	1.9 1.1 0.8	68 21 1 6

#	Article	IF	CITATIONS
390	Nurr1 promotes neurogenesis of dopaminergic neuron and represses inflammatory factors in the transwell coculture system of neural stem cells and microglia. CNS Neuroscience and Therapeutics, 2018, 24, 790-800.	1.9	25
391	Deep Brain Stimulation of the Subthalamic Nucleus Parameter Optimization for Vowel Acoustics and Speech Intelligibility in Parkinson's Disease. Journal of Speech, Language, and Hearing Research, 2018, 61, 510-524.	0.7	15
392	The neuroprotective role of melatonin in neurological disorders. Journal of Neuroscience Research, 2018, 96, 1136-1149.	1.3	154
393	Test for Non-Synergistic Interactions in Phytomedicine, Just as You Do for Isolated Compounds. Journal of Experimental Neuroscience, 2018, 12, 117906951876765.	2.3	1
394	<i>MAOâ€B</i> and <i>COMT</i> Genetic Variations Associated With Levodopa Treatment Response in Patients With Parkinson's Disease. Journal of Clinical Pharmacology, 2018, 58, 920-926.	1.0	51
395	Descriptive epidemiology of parkinsonism in the Canton of Geneva, Switzerland. Parkinsonism and Related Disorders, 2018, 54, 30-39.	1.1	42
396	Cellular Senescence Is Induced by the Environmental Neurotoxin Paraquat and Contributes to Neuropathology Linked to Parkinson's Disease. Cell Reports, 2018, 22, 930-940.	2.9	342
397	Smoking and Parkinson disease. Neurology, 2018, 90, e583-e592.	1.5	27
398	2,5-Hexanedione induces dopaminergic neurodegeneration through integrin αMβ2/NADPH oxidase axis-mediated microglial activation. Cell Death and Disease, 2018, 9, 60.	2.7	23
399	Alpha-synucleinopathies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 145, 339-353.	1.0	50
400	The choroid plexus epithelium as a novel player in the stomach-brain axis during Helicobacter infection. Brain, Behavior, and Immunity, 2018, 69, 35-47.	2.0	28
401	The Pivotal Role of Copper in Neurodegeneration: A New Strategy for the Therapy of Neurodegenerative Disorders. Molecular Pharmaceutics, 2018, 15, 808-820.	2.3	84
402	Letter to the Editor: Regarding Foster et al., Neonatal C57BL/6J and parkin mice respond differently following developmental manganese exposure: Result of a high dose pilot study. NeuroToxicology, 2018, 69, 187.	1.4	0
403	Exploring cancer in <i><scp>LRRK</scp>2</i> mutation carriers and idiopathic Parkinson's disease. Brain and Behavior, 2018, 8, e00858.	1.0	19
404	A Groundbreaking Technology in Virtual Rehabilitation to Improve Falls in Older People. Advances in Intelligent Systems and Computing, 2018, , 1251-1261.	0.5	1
405	Body mass index, sitting time, and risk of Parkinson disease. Neurology, 2018, 90, e1413-e1417.	1.5	22
406	Non-human primate models of PD to test novel therapies. Journal of Neural Transmission, 2018, 125, 291-324.	1.4	29
407	Association of soil selenium, strontium, and magnesium concentrations with Parkinson's disease mortality rates in the USA. Environmental Geochemistry and Health, 2018, 40, 349-357.	1.8	22

#	Article	IF	CITATIONS
408	Short-term association between road traffic noise and healthcare demand generated by Parkinson's disease in Madrid, Spain. Gaceta Sanitaria, 2018, 32, 553-558.	0.6	7
409	Olfactory toxicity in rats following manganese chloride nasal instillation: A pilot study. NeuroToxicology, 2018, 64, 284-290.	1.4	16
410	Neonatal C57BL/6J and parkin mice respond differently following developmental manganese exposure: Result of a high dose pilot study. NeuroToxicology, 2018, 64, 291-299.	1.4	6
411	Autoimmune rheumatic diseases and the risk of Parkinson disease: a nationwide population-based cohort study in Taiwan. Annals of Medicine, 2018, 50, 83-90.	1.5	46
412	Epidemiology of Parkinson's Disease—East Versus West. Movement Disorders Clinical Practice, 2018, 5, 14-28.	0.8	114
413	Tonsillectomy and risk of Parkinson's disease: A danish nationwide populationâ€based cohort study. Movement Disorders, 2018, 33, 321-324.	2.2	6
414	Alpha-synuclein aggregation, Ubiquitin proteasome system impairment, and l-Dopa response in zinc-induced Parkinsonism: resemblance to sporadic Parkinson's disease. Molecular and Cellular Biochemistry, 2018, 444, 149-160.	1.4	43
415	Considerations for general anaesthesia in Parkinson's disease. Journal of Clinical Neuroscience, 2018, 48, 34-41.	0.8	18
416	Different Exposures to Risk Factors Do Not Explain the Inverse Relationship of Occurrence Between Cancer and Neurodegenerative Diseases. Alzheimer Disease and Associated Disorders, 2018, 32, 76-82.	0.6	4
417	Reduced workforce participation 5 years prior to first Parkinson's disease sick-leave. Npj Parkinson's Disease, 2018, 4, 36.	2.5	2
418	Nicotine promotes neuron survival and partially protects from Parkinson's disease by suppressing SIRT6. Acta Neuropathologica Communications, 2018, 6, 120.	2.4	58
419	Familial aggregation of Parkinson's disease and coaggregation with neuropsychiatric diseases: a population-based cohort study. Clinical Epidemiology, 2018, Volume 10, 631-641.	1.5	7
420	Enfermedad de Parkinson: fisiopatologÃa, diagnÃ <sup>3</sup> stico y tratamiento. Revista De La Universidad Industrial De Santander Salud, 2018, 50, 79-92.	0.0	7
421	Parkinsonism in Inherited Metabolic Disorders: Key Considerations and Major Features. Frontiers in Neurology, 2018, 9, 857.	1.1	15
422	Counteracting neuroinflammation in experimental Parkinson's disease favors recovery of function: effects of Er-NPCs administration. Journal of Neuroinflammation, 2018, 15, 333.	3.1	16
423	Hypotension and bradycardia, a serious adverse effect of piribedil, a case report and literature review. BMC Neurology, 2018, 18, 221.	0.8	6
424	Sex-Specific Transcriptome Differences in Substantia Nigra Tissue: A Meta-Analysis of Parkinson's Disease Data. Genes, 2018, 9, 275.	1.0	16
425	Association of Levels of Physical Activity With Risk of Parkinson Disease. JAMA Network Open, 2018, 1, e182421.	2.8	94

		CITATION REPORT	
#	ARTICLE	IF	CITATIONS
426	Increased risk of diseases of the basal ganglia and cerebellum in patients with a history of attention-deficit/hyperactivity disorder. Neuropsychopharmacology, 2018, 43, 2548-2555.	2.8	43
427	What About the Role of Virtual Reality in Parkinson Disease's Cognitive Rehabilitation? Prelin Findings From a Randomized Clinical Trial. Journal of Geriatric Psychiatry and Neurology, 2018, 3 312-318.	minary 31, 1.2	75
429	Potential Metabolomic Linkage in Blood between Parkinson's Disease and Traumatic Brain Ir Metabolites, 2018, 8, 50.	njury. 1.3	14
430	Social influences on microglial reactivity and neuronal damage after cardiac arrest/cardiopulmor resuscitation. Physiology and Behavior, 2018, 194, 437-449.	nary 1.0	11
432	Parkinson's diseaseâ€associated protein Parkin: an unusual player in cancer. Cancer Communica 2018, 38, 1-8.	ations, 3.7	36
433	The Length of SNCA Rep1 Microsatellite May Influence Cognitive Evolution in Parkinson's Di Frontiers in Neurology, 2018, 9, 213.	isease. 1.1	21
434	Inhibition of microRNA-505 suppressed MPP+â€⁻-induced cytotoxicity of SHSY5Y cells in an in vi Parkinson's disease model. European Journal of Pharmacology, 2018, 835, 11-18.	itro 1.7	22
435	Evidence for Compartmentalized Axonal Mitochondrial Biogenesis: Mitochondrial DNA Replication Increases in Distal Axons As an Early Response to Parkinson's Disease-Relevant Stress. Journal of Neuroscience, 2018, 38, 7505-7515.	on 	51
436	Association of Parkinson's disease with industry sectors: a French nationwide incidence stud European Journal of Epidemiology, 2018, 33, 1101-1111.	dy. 2.5	25
437	Therapeutic efficacy of olfactory stem cells in rotenone induced Parkinsonism in adult male albir rats. Biomedicine and Pharmacotherapy, 2018, 103, 1178-1186.	10 2.5	10
438	Use of medical care biases associations between Parkinson disease and other medical condition Neurology, 2018, 90, e2155-e2165.	s. 1.5	17
439	Effects of ambient air pollution on incident Parkinson's disease in Ontario, 2001 to 2013: a population-based cohort study. International Journal of Epidemiology, 2018, 47, 2038-2048.	0.9	69
440	Prática mental após fisioterapia mantém mobilidade funcional de pessoas com doença de Fisioterapia E Pesquisa, 2018, 25, 65-73.	Parkinson. 0.3	6
441	Utilization of Chinese herbal medicine and its association with the risk of fracture in patients wit Parkinson's disease in Taiwan. Journal of Ethnopharmacology, 2018, 226, 168-175.	th 2.0	10
442	An updated analysis with 45,078 subjects confirms the association between SNCA rs11931074 Parkinson's disease. Neurological Sciences, 2018, 39, 2061-2069.	and 0.9	2
443	General Overview of Toxicology. , 2018, , 1-38.		1
444	Effects of blackberry ( <em>Morus nigra</em> ) fruit juice on levodopa-induced dyskin a mice model of Parkinson's disease. Journal of Experimental Pharmacology, 2018, Vo 29-35.		10
445	Higher serum cholesterol and decreased Parkinson's disease risk: A statinâ€free cohort study. Movement Disorders, 2018, 33, 1298-1305.	2.2	89

#	Article	IF	CITATIONS
446	Musical Feature Based Classification of Parkinson's Disease Using Dysphonic Speech. , 2018, , .		3
447	Deltamethrin Intranasal administration induces memory, emotional and tyrosine hydroxylase immunoreactivity alterations in rats. Brain Research Bulletin, 2018, 142, 297-303.	1.4	21
448	A workflow for the integrative transcriptomic description of molecular pathology and the suggestion of normalizing compounds, exemplified by Parkinson's disease. Scientific Reports, 2018, 8, 7937.	1.6	5
449	Childhood Lead Exposure and Adult Neurodegenerative Disease. Journal of Alzheimer's Disease, 2018, 64, 17-42.	1.2	70
450	Spatial Distribution of Parkinson's Disease Prevalence in Québec by Hydrographic Region. Canadian Journal of Neurological Sciences, 2018, 45, 478-480.	0.3	1
451	Potential Therapeutic Application for Nicotinic Receptor Drugs in Movement Disorders. Nicotine and Tobacco Research, 2019, 21, 357-369.	1.4	26
452	Case of Early-Onset Parkinson's Disease in a Heterozygous Mutation Carrier of the ATP7B Gene. Journal of Personalized Medicine, 2019, 9, 41.	1.1	6
453	Patients with Inflammatory Bowel Disease Are at an Increased Risk of Parkinson's Disease: A South Korean Nationwide Population-Based Study. Journal of Clinical Medicine, 2019, 8, 1191.	1.0	60
454	Nutritional Risk Factors, Microbiota and Parkinson's Disease: What Is the Current Evidence?. Nutrients, 2019, 11, 1896.	1.7	69
455	NEAT1 is overexpressed in Parkinson's disease substantia nigra and confers drugâ€inducible neuroprotection from oxidative stress. FASEB Journal, 2019, 33, 11223-11234.	0.2	73
456	Integration of curated and high-throughput screening data to elucidate environmental influences on disease pathways. Computational Toxicology, 2019, 12, 100094.	1.8	13
457	The role of one-carbon metabolism and homocysteine in Parkinson's disease onset, pathology and mechanisms. Nutrition Research Reviews, 2019, 32, 218-230.	2.1	37
458	Infectious Etiologies of Parkinsonism: Pathomechanisms and Clinical Implications. Frontiers in Neurology, 2019, 10, 652.	1.1	91
459	Genetic and Environmental Factors Contributing to Parkinson's Disease: A Case-Control Study in the Cypriot Population. Frontiers in Neurology, 2019, 10, 1047.	1.1	20
460	Erythropoietin as a Neuroprotective Molecule: An Overview of Its Therapeutic Potential in Neurodegenerative Diseases. ASN Neuro, 2019, 11, 175909141987142.	1.5	61
461	Helicobacter suis Is Associated With Mortality in Parkinson's Disease. Frontiers in Medicine, 2019, 6, 188.	1.2	14
462	Chloramphenicol Mitigates Oxidative Stress by Inhibiting Translation of Mitochondrial Complex I in Dopaminergic Neurons of Toxin-Induced Parkinson's Disease Model. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-14.	1.9	8
463	An NMR-based lipidomic approach to identify Parkinson's disease-stage specific lipoprotein–lipid signatures in plasma. Analyst, The, 2019, 144, 1334-1344.	1.7	9

#	Article	IF	CITATIONS
464	Time Trends of the Incidence, Prevalence, and Mortality of Parkinsonism. Canadian Journal of Neurological Sciences, 2019, 46, 184-191.	0.3	6
465	Impulse control disorders in Parkinson's disease: A systematic review on risk factors and pathophysiology. Journal of the Neurological Sciences, 2019, 398, 101-106.	0.3	25
466	miRNAs and target genes in the blood as biomarkers for the early diagnosis of Parkinson's disease. BMC Systems Biology, 2019, 13, 10.	3.0	25
467	Epigenetic and Neurological Impairments Associated with Early Life Exposure to Persistent Organic Pollutants. International Journal of Genomics, 2019, 2019, 1-19.	0.8	74
468	NEAT1 regulates MPP+-induced neuronal injury by targeting miR-124 in neuroblastoma cells. Neuroscience Letters, 2019, 708, 134340.	1.0	46
469	Objective and Subjective Speech Quality Assessment of Amplification Devices for Patients With Parkinson's Disease. IEEE Transactions on Neural Systems and Rehabilitation Engineering, 2019, 27, 1226-1235.	2.7	13
470	A secret that underlies Parkinson's disease: The damaging cycle. Neurochemistry International, 2019, 129, 104484.	1.9	21
471	Kin-FOG: Automatic Simulated Freezing of Gait (FOG) Assessment System for Parkinson's Disease. Sensors, 2019, 19, 2416.	2.1	10
472	Identification of potential diagnostic biomarkers for Parkinson's disease. FEBS Open Bio, 2019, 9, 1460-1468.	1.0	36
473	The association between Parkinson's disease and temporomandibular disorder. PLoS ONE, 2019, 14, e0217763.	1.1	10
474	Mitochondrially targeted cytochrome P450 2D6 is involved in monomethylamine-induced neuronal damage in mouse models. Journal of Biological Chemistry, 2019, 294, 10336-10348.	1.6	10
475	Statistical Shape Analysis of Subthalamic Nucleus in Patients with Parkinson Disease. World Neurosurgery, 2019, 126, e835-e841.	0.7	13
476	Divergent Expression Patterns of Drp1 and HSD10 in the Nigro-Striatum of Two Mice Strains Based on their MPTP Susceptibility. Neurotoxicity Research, 2019, 36, 27-38.	1.3	11
477	Measurement of serum cystatin C: A valuable tool for evaluating dyskinesia in Parkinson's disease. Neuroscience Letters, 2019, 705, 172-176.	1.0	3
478	Discordance in monozygotic Parkinson's disease twins – continuum or dichotomy?. Annals of Clinical and Translational Neurology, 2019, 6, 1102-1105.	1.7	4
479	A transversal study of fundamental frequency contours in parkinsonian voices. Biomedical Signal Processing and Control, 2019, 51, 374-381.	3.5	2
480	Chronic renal dysfunction, proteinuria, and risk of Parkinson's disease in the elderly. Movement Disorders, 2019, 34, 1184-1191.	2.2	33
482	Molecular chaperones biochemistry and role in neurodegenerative diseases. International Journal of Biological Macromolecules, 2019, 131, 396-411.	3.6	18

#	Article	IF	CITATIONS
483	Covalent Modification and Regulation of the Nuclear Receptor Nurr1 by a Dopamine Metabolite. Cell Chemical Biology, 2019, 26, 674-685.e6.	2.5	41
484	Anemia in men and increased Parkinson's disease risk: A population-based large scale cohort study. Parkinsonism and Related Disorders, 2019, 64, 90-96.	1.1	10
485	The Parkinson's phenome—traits associated with Parkinson's disease in a broadly phenotyped cohort. Npj Parkinson's Disease, 2019, 5, 4.	2.5	34
486	Cardiovascular risk factors and Parkinson's disease in 500,000 Chinese adults. Annals of Clinical and Translational Neurology, 2019, 6, 624-632.	1.7	26
487	Economic Evaluation of Interventions in Parkinson's Disease: A Systematic Literature Review. Movement Disorders Clinical Practice, 2019, 6, 282-290.	0.8	25
488	Older Adults. , 2019, , 455-480.		0
489	Diet and medical foods in Parkinson's disease. Food Science and Human Wellness, 2019, 8, 83-95.	2.2	22
490	Neuroprotection, Recovery of Function and Endogenous Neurogenesis in Traumatic Spinal Cord Injury Following Transplantation of Activated Adipose Tissue. Cells, 2019, 8, 329.	1.8	20
491	<i>N</i> -Methyl-4-phenylpyridinium Scaffold-Containing Lipophilic Compounds Are Potent Complex I Inhibitors and Selective Dopaminergic Toxins. ACS Chemical Neuroscience, 2019, 10, 2977-2988.	1.7	4
492	Recapitulating Parkinson's disease pathology in a three-dimensional human neural cell culture model. DMM Disease Models and Mechanisms, 2019, 12, .	1.2	31
493	Neurobehavioral performance of patients diagnosed with manganism and idiopathic Parkinson disease. International Archives of Occupational and Environmental Health, 2019, 92, 383-394.	1.1	12
494	Retinal α-synuclein deposits in Parkinson's disease patients and animal models. Acta Neuropathologica, 2019, 137, 379-395.	3.9	79
495	The characteristics and treatment patterns of patients with Parkinson's disease in the United States and United Kingdom: A retrospective cohort study. PLoS ONE, 2019, 14, e0225723.	1.1	13
496	Cannabidiol Protects Dopaminergic Neuronal Cells from Cadmium. International Journal of Environmental Research and Public Health, 2019, 16, 4420.	1.2	30
497	Diabetes, a Contemporary Risk for Parkinson's Disease: Epidemiological and Cellular Evidences. Frontiers in Aging Neuroscience, 2019, 11, 302.	1.7	53
498	Estimation of Pathological Hand Tremor Signals by Fourier Linear Combiner Based Online Censoring LMS Algorithm. , 2019, , .		2
499	Dysregulated Long Non-coding RNAs in Parkinson's Disease Contribute to the Apoptosis of Human Neuroblastoma Cells. Frontiers in Neuroscience, 2019, 13, 1320.	1.4	43
500	Cell models of lipid-rich α-synuclein aggregation validate known modifiers of α-synuclein biology and identify stearoyl-CoA desaturase. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 20760-20769.	3.3	64

#	Article	IF	CITATIONS
501	The effect of balance training with Tetra-ataxiometric posturography on balance function in patients with parkinsonism. NeuroRehabilitation, 2019, 45, 379-384.	0.5	2
502	Mobile phone applications in Parkinson's disease: a systematic review. NeurologÃa (English Edition), 2019, 34, 38-54.	0.2	42
503	Accuracy of Transcranial Sonography of the Substantia Nigra for Detection of Parkinson's Disease: A Systematic Review and Meta-analysis. Ultrasound in Medicine and Biology, 2019, 45, 628-641.	0.7	31
504	Gout and the risk of Parkinson's disease in older adults: a study of U.S. Medicare data. BMC Neurology, 2019, 19, 4.	0.8	23
505	Nanoengineered biomaterial for brain tissue reconstruction and functional repairment. , 2019, , 145-166.		3
506	The Role of the Neuropsychologist in Deep Brain Stimulation. , 2019, , 185-228.		0
507	Haptics-enabled Interactive NeuroRehabilitation Mechatronics: Classification, Functionality, Challenges and Ongoing Research. Mechatronics, 2019, 57, 1-19.	2.0	30
508	Caring Interactions in Secondary Prevention Programs: A Qualitative Inquiry of Individuals With Parkinson's Disease. Journal of Geriatric Physical Therapy, 2019, 42, 167-175.	0.6	5
509	Aplicaciones móviles en la enfermedad de Parkinson: una revisión sistemática. NeurologÃa, 2019, 34, 38-54.	0.3	39
510	An outlook on the role of decaffeinated coffee in neurodegenerative diseases. Critical Reviews in Food Science and Nutrition, 2020, 60, 760-779.	5.4	28
511	The Role of Sex and Sex Hormones in Neurodegenerative Diseases. Endocrine Reviews, 2020, 41, 273-319.	8.9	118
512	Experiences and feelings of patients with Parkinson's. EnfermerÃa ClÃnica (English Edition), 2020, 30, 253-259.	0.1	1
513	Parkinson Disease. , 2020, , 806-810.		1
514	Correlations between blood lipid, serum cystatin C, and homocysteine levels in patients with Parkinson's disease. Psychogeriatrics, 2020, 20, 180-188.	0.6	16
515	The impact of long-term exposure to ambient air pollution and second-hand smoke on the onset of Parkinson disease: a review and meta-analysis. Public Health, 2020, 179, 100-110.	1.4	36
516	Is Parkinson's Disease a Very Rare Pathology in Centenarians? A Clinical Study in a Cohort of Subjects. Journal of Alzheimer's Disease, 2020, 73, 73-76.	1.2	4
517	Obstructive sleep apnea, CPAP therapy and Parkinson's disease motor function: A longitudinal study. Parkinsonism and Related Disorders, 2020, 70, 45-50.	1.1	35
518	Long-term effects of PM2·5 on neurological disorders in the American Medicare population: a longitudinal cohort study. Lancet Planetary Health, The, 2020, 4, e557-e565.	5.1	151

#	Article	IF	CITATIONS
519	Relationship between circulating CD4+ T lymphocytes and cognitive impairment in patients with Parkinson's disease. Brain, Behavior, and Immunity, 2020, 89, 668-674.	2.0	39
520	Oxidative Damage of Blood Platelets Correlates with the Degree of Psychophysical Disability in Secondary Progressive Multiple Sclerosis. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-12.	1.9	7
521	Inflammation in Parkinson's Disease: Mechanisms and Therapeutic Implications. Cells, 2020, 9, 1687.	1.8	334
522	Advances in Tissue Engineering and Innovative Fabrication Techniques for 3-D-Structures: Translational Applications in Neurodegenerative Diseases. Cells, 2020, 9, 1636.	1.8	35
523	Seaweeds' neuroprotective potential set in vitro on a human cellular stress model. Molecular and Cellular Biochemistry, 2020, 473, 229-238.	1.4	8
524	High IQ in Early Adulthood Is Associated with Parkinson's Disease. Journal of Parkinson's Disease, 2020, 10, 1649-1656.	1.5	11
525	Efficacy and Acceptance of a Lombard-response Device for Hypophonia in Parkinson's Disease. Canadian Journal of Neurological Sciences, 2020, 47, 634-641.	0.3	3
526	Rapamycin, by Inhibiting mTORC1 Signaling, Prevents the Loss of Striatal Bidirectional Synaptic Plasticity in a Rat Model of L-DOPA-Induced Dyskinesia. Frontiers in Aging Neuroscience, 2020, 12, 230.	1.7	18
527	Efficacy and Characteristics of the Stimuli of Action Observation Therapy in Subjects With Parkinson's Disease: A Systematic Review. Frontiers in Neurology, 2020, 11, 808.	1.1	15
528	The impact of music interventions on motor rehabilitation following stroke in elderly. , 2020, , 407-432.		8
529	Real-world safety and effectiveness of rotigotine in patients with Parkinson's disease: analysis of a post-marketing surveillance study in Japan. International Journal of Neuroscience, 2020, , 1-11.	0.8	0
530	Cerebrospinal fluid monocyte chemoattractant protein 1 correlates with progression of Parkinson's disease. Npj Parkinson's Disease, 2020, 6, 21.	2.5	17
531	Milk and Fermented Milk Intake and Parkinson's Disease: Cohort Study. Nutrients, 2020, 12, 2763.	1.7	18
532	Effects of Smoking on Regional Homogeneity in Mild Cognitive Impairment: A Resting-State Functional MRI Study. Frontiers in Aging Neuroscience, 2020, 12, 572732.	1.7	4
533	Resting Heart Rate Variability Is Associated With Subsequent Orthostatic Hypotension: Comparison Between Healthy Older People and Patients With Rapid Eye Movement Sleep Behavior Disorder. Frontiers in Neurology, 2020, 11, 567984.	1.1	7
534	Functional Pathway Identification With CRISPR/Cas9 Genome-wide Gene Disruption in Human Dopaminergic Neuronal Cells Following Chronic Treatment With Dieldrin. Toxicological Sciences, 2020, 176, 366-381.	1.4	14
535	Transgenic Overexpression of GPNMB Protects Against MPTP-Induced Neurodegeneration. Molecular Neurobiology, 2020, 57, 2920-2933.	1.9	20
536	Psychosocial Adjustment of In-Home Caregivers of Family Members with Dementia and Parkinson's Disease: A Comparative Study. Parkinson's Disease, 2020, 2020, 1-10.	0.6	3

#	Article	IF	CITATIONS
537	Remote tracking of Parkinson's Disease progression using ensembles of Deep Belief Network and Self-Organizing Map. Expert Systems With Applications, 2020, 159, 113562.	4.4	49
538	Treatment of Dysphagia in Parkinson's Disease: A Systematic Review. International Journal of Environmental Research and Public Health, 2020, 17, 4104.	1.2	40
539	Conductive Hydrogels—A Novel Material: Recent Advances and Future Perspectives. Journal of Agricultural and Food Chemistry, 2020, 68, 7269-7280.	2.4	60
540	Clostridium difficile infection and risk of Parkinson's disease: a Swedish populationâ€based cohort study. European Journal of Neurology, 2020, 27, 2134-2141.	1.7	14
541	Validation of a Parkinson Disease Predictive Model in a Population-Based Study. Parkinson's Disease, 2020, 2020, 1-7.	0.6	5
542	miRâ€30b protects nigrostriatal dopaminergic neurons from MPP(+)â€induced neurotoxicity via SNCA. Brain and Behavior, 2020, 10, e01567.	1.0	24
543	Metformin protects rotenone-induced dopaminergic neurodegeneration by reducing lipid peroxidation. Pharmacological Reports, 2020, 72, 1397-1406.	1.5	21
544	The TANDEM investigation: efficacy and tolerability of levodopa-carbidopa intestinal gel in (LCIG) advanced Parkinson's disease patients. Journal of Neural Transmission, 2020, 127, 881-891.	1.4	8
545	What and How Can Physical Activity Prevention Function on Parkinson's Disease?. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-12.	1.9	33
546	Parkinson's Disease in Louisiana, 1999–2012: Based on Hospital Primary Discharge Diagnoses, Incidence, and Risk in Relation to Local Agricultural Crops, Pesticides, and Aquifer Recharge. International Journal of Environmental Research and Public Health, 2020, 17, 1584.	1.2	12
547	Parkinson's disease case ascertainment in prospective cohort studies through combining multiple health information resources. PLoS ONE, 2020, 15, e0234845.	1.1	6
548	Parkinson's disease a futile entangle of Mankind's credence on an herbal remedy: A review. Life Sciences, 2020, 257, 118019.	2.0	0
549	The Effect of Caffeine on the Risk and Progression of Parkinson's Disease: A Meta-Analysis. Nutrients, 2020, 12, 1860.	1.7	53
550	The expression change of glial fibrillary acidic protein and tyrosine hydroxylase in substantia nigra of the Wistar rats exposed to chlorpyrifos: a novel environmental risk factor for Parkinson's disease. Experimental Brain Research, 2020, 238, 2041-2051.	0.7	6
551	Handheld Cough Testing: A Novel Tool for Cough Assessment and Dysphagia Screening. Dysphagia, 2020, 35, 993-1000.	1.0	17
552	Strategies for the Treatment of Parkinson's Disease: Beyond Dopamine. Frontiers in Aging Neuroscience, 2020, 12, 4.	1.7	74
553	Diagnostic Performance of Transcranial Sonography for Evaluating Substantia Nigra Hyper-echogenicity in Patients with Parkinson's Disease. Ultrasound in Medicine and Biology, 2020, 46, 1208-1215.	0.7	8
554	Spinal versus General Anesthesia for Patients with Parkinson's Disease. International Journal of General Medicine, 2020, Volume 13, 9-15.	0.8	5

#	Article	IF	CITATIONS
555	Mechanisms of alpha-synuclein toxicity: An update and outlook. Progress in Brain Research, 2020, 252, 91-129.	0.9	49
556	The benefits and mechanisms of exercise training for Parkinson's disease. Life Sciences, 2020, 245, 117345.	2.0	92
557	Road proximity, air pollution, noise, green space and neurologic disease incidence: a population-based cohort study. Environmental Health, 2020, 19, 8.	1.7	106
558	Design, synthesis and identification of N, N-dibenzylcinnamamide (DBC) derivatives as novel ligands for α-synuclein fibrils by SPR evaluation system. Bioorganic and Medicinal Chemistry, 2020, 28, 115358.	1.4	9
559	PHLDA1 promotes microglia-mediated neuroinflammation via regulating K63-linked ubiquitination of TRAF6. Brain, Behavior, and Immunity, 2020, 88, 640-653.	2.0	28
560	Clinical Efficacy and Transcriptomic Analysis of Congrong Shujing Granules (è‹è́"‰è^'痉颗粒) in Patients wit Parkinson's Disease and Syndrome of Shen (Kidney) Essence Deficiency. Chinese Journal of Integrative Medicine, 2020, 26, 412-419.	:h 0.7	5
561	Deep Learning Approaches for Detecting Freezing of Gait in Parkinson's Disease Patients through On-Body Acceleration Sensors. Sensors, 2020, 20, 1895.	2.1	62
562	Historical Perspective: Models of Parkinson's Disease. International Journal of Molecular Sciences, 2020, 21, 2464.	1.8	174
563	Brief Cognitive Behavioral Therapy for Insomnia in Parkinson's Disease: A Case Series Study <sup>1</sup> . Japanese Psychological Research, 2021, 63, 59-71.	0.4	4
564	Linking chronic kidney disease and Parkinson's disease: a literature review. Metabolic Brain Disease, 2021, 36, 1-12.	1.4	18
565	Fasting plasma glucose variability in midlife and risk of Parkinson's disease: A nationwide population-based study. Diabetes and Metabolism, 2021, 47, 101195.	1.4	13
566	Inflammatory IncRNA AK039862 regulates paraquat-inhibited proliferation and migration of microglial and neuronal cells through the Pafah1b1/Foxa1 pathway in co-culture environments. Ecotoxicology and Environmental Safety, 2021, 208, 111424.	2.9	9
567	Factors explaining physical activity level in Parkinson´s disease: A gender focus. Physiotherapy Theory and Practice, 2021, 37, 507-516.	0.6	22
568	Adaptive Fourier linear combiner based on modified least mean Kurtosis algorithm for the processing of sinusoidal signals. Transactions of the Institute of Measurement and Control, 2021, 43, 1039-1047.	1.1	2
569	Evaluation of the Association Between Serum Levels of Testosterone and Prolactin With 6- Hydroxydopamine- Induced Parkinsonism in Male Rats. Basic and Clinical Neuroscience, 2021, 12, 453-464.	0.3	0
570	An Introduction to Cancer Biomarkers. , 2021, , 1-12.		0
572	Non-genetic risk and protective factors and biomarkers for neurological disorders: a meta-umbrella systematic review of umbrella reviews. BMC Medicine, 2021, 19, 6.	2.3	29
573	Solvent exposed occupations and risk of Parkinson disease in Finland. Clinical Parkinsonism & Related Disorders, 2021, 4, 100092.	0.5	5

#	Article	IF	CITATIONS
575	The effectiveness of specialized nursing interventions for patients with Parkinson disease. Medicine (United States), 2021, 100, e23972.	0.4	2
576	Program of Seven 45-min Dry Immersion Sessions Improves Choice Reaction Time in Parkinson's Disease. Frontiers in Physiology, 2020, 11, 621198.	1.3	9
577	Parkinson's Disease and Impairment in Mitochondrial Metabolism: A Pathognomic Signature. Advances in Experimental Medicine and Biology, 2021, 1286, 65-76.	0.8	4
578	Functions and Therapeutic Potential of Extracellular Hsp60, Hsp70, and Hsp90 in Neuroinflammatory Disorders. Applied Sciences (Switzerland), 2021, 11, 736.	1.3	14
579	Parkinson disease detection using energy direction features based on EMD from voice signal. Biocybernetics and Biomedical Engineering, 2021, 41, 127-141.	3.3	40
580	A Deep Learning Based Method for Parkinson's Disease Detection Using Dynamic Features of Speech. IEEE Access, 2021, 9, 10239-10252.	2.6	58
581	Automatic Resting Tremor Assessment in Parkinson's Disease Using Smartwatches and Multitask Convolutional Neural Networks. Sensors, 2021, 21, 291.	2.1	43
582	<i>Caenorhabditis elegans</i> Model Studies Show MPP <sup>+</sup> Is a Simple Member of a Large Group of Related Potent Dopaminergic Toxins. Chemical Research in Toxicology, 2021, 34, 1275-1285.	1.7	5
583	Environmental Aspects of Alzheimer's and Parkinson's Diseases Neuropathologies. , 2021, , 79-108.		0
584	Peptide Profile of Zebrafish Brain in a 6-OHDA-Induced Parkinson Model. Zebrafish, 2021, 18, 55-65.	0.5	5
585	Glucocerebrosidase reduces the spread of protein aggregation in a Drosophila melanogaster model of neurodegeneration by regulating proteins trafficked by extracellular vesicles. PLoS Genetics, 2021, 17, e1008859.	1.5	20
587	Geospatial analysis of individual-based Parkinson's disease data supports a link with air pollution: A case-control study. Parkinsonism and Related Disorders, 2021, 83, 41-48.	1.1	18
588	Correlation between depression and quality of life in patients with Parkinson's disease. Clinical Neurology and Neurosurgery, 2021, 202, 106523.	0.6	23
589	Public Engagement and Neurology: An Update. Brain Sciences, 2021, 11, 429.	1.1	5
590	Association Between Microscopic Colitis and Parkinson's Disease in a Swedish Population. Movement Disorders, 2021, 36, 1919-1926.	2.2	9
591	SIRT1 Deacetylates TET2 and Promotes Its Ubiquitination Degradation to Achieve Neuroprotection Against Parkinson's Disease. Frontiers in Neurology, 2021, 12, 652882.	1.1	10
592	Variable Effects of PD-Risk Associated SNPs and Variants in Parkinsonism-Associated Genes on Disease Phenotype in a Community-Based Cohort. Frontiers in Neurology, 2021, 12, 662278.	1.1	4
593	Cost-Effectiveness of Device-Aided Therapies in Parkinson's Disease: A Structured Review. Journal of Parkinson's Disease, 2021, 11, 475-489.	1.5	11

#	Article	IF	CITATIONS
594	Microalbuminuria as a potential biomarker for Parkinson's disease severity: A hypothesis. Medical Hypotheses, 2021, 149, 110510.	0.8	0
595	Management of Hypertension and Blood Pressure Dysregulation in Patients with Parkinson's Disease—a Systematic Review. Current Hypertension Reports, 2021, 23, 26.	1.5	7
596	Mortality from Parkinson's disease and other causes among a workforce manufacturing paraquat: an updated retrospective cohort study. Journal of Occupational Medicine and Toxicology, 2021, 16, 20.	0.9	3
597	Performance Evaluation of RNN with Hyperbolic Secant in Gate Structure through Application of Parkinson's Disease Detection. Applied Sciences (Switzerland), 2021, 11, 4361.	1.3	10
598	Parkinson's disease: Alterations in iron and redox biology as a key to unlock therapeutic strategies. Redox Biology, 2021, 41, 101896.	3.9	75
599	No detectable effect on visual responses using functional MRI in a rodent model of α-synuclein expression. ENeuro, 2021, 8, ENEURO.0516-20.2021.	0.9	0
600	Association of Dynamic Changes in Metabolic Syndrome Status with the Risk of Parkinson's Disease: A Nationwide Cohort Study. Journal of Parkinson's Disease, 2021, 11, 1-9.	1.5	3
601	Pesticides expenditures by farming type and incidence of Parkinson disease in farmers: A French nationwide study. Environmental Research, 2021, 197, 111161.	3.7	8
602	Case-control study of hypertension and Parkinson's disease. Npj Parkinson's Disease, 2021, 7, 63.	2.5	8
604	Present and Future of Parkinson's Disease in Spain: PARKINSON-2030 Delphi Project. Brain Sciences, 2021, 11, 1027.	1.1	6
605	Exposure to low-dose ambient fine particulate matter PM2.5 and Alzheimer's disease, non-Alzheimer's dementia, and Parkinson's disease in North Carolina. PLoS ONE, 2021, 16, e0253253.	1.1	38
606	Oxidative stress parameters as biomarkers of bladder cancer development and progression. Scientific Reports, 2021, 11, 15134.	1.6	24
607	Myrtenol complexed with βâ€cyclodextrin ameliorates behavioural deficits and reduces oxidative stress in the reserpineâ€induced animal model of Parkinsonism. Clinical and Experimental Pharmacology and Physiology, 2021, 48, 1488-1499.	0.9	5
608	The epigenetic mechanisms involved in mitochondrial dysfunction: Implication for Parkinson's disease. Brain Pathology, 2022, 32, e13012.	2.1	11
609	Rice bran, an off-shoot to newer therapeutics in neurological disorders. Biomedicine and Pharmacotherapy, 2021, 140, 111796.	2.5	19
610	A Comparative Study of Time Frequency Representation Techniques for Freeze of Gait Detection and Prediction. Sensors, 2021, 21, 6446.	2.1	10
611	DJ-1 and Parkinson's disease. Brain Disorders, 2021, 3, 100020.	1.1	2
612	A mitochondria-targeted caffeic acid derivative reverts cellular and mitochondrial defects in human skin fibroblasts from male sporadic Parkinson's disease patients. Redox Biology, 2021, 45, 102037.	3.9	15

#	Article	IF	CITATIONS
613	Cholinergic Receptor Modulation as a Target for Preventing Dementia in Parkinson's Disease. Frontiers in Neuroscience, 2021, 15, 665820.	1.4	14
614	Does paraquat cause Parkinson's disease? A review of reviews. NeuroToxicology, 2021, 86, 180-184.	1.4	15
615	Validity of the modified sphygmomanometer test for the assessment of tip pinch strength in Parkinson's disease. Journal of Bodywork and Movement Therapies, 2021, 28, 87-91.	0.5	1
616	Persistent Organic Pollutants and Neurological Disorders: From Exposure to Preventive Interventions. Emerging Contaminants and Associated Treatment Technologies, 2021, , 231-247.	0.4	3
617	Dietary Antioxidants and the Risk of Parkinson Disease. Neurology, 2021, 96, e895-e903.	1.5	36
618	Nutrition and Gastrointestinal Health as Modulators of Parkinson's Disease. AAPS Advances in the Pharmaceutical Sciences Series, 2014, , 213-242.	0.2	5
619	Metals and Paraoxonases. Advances in Neurobiology, 2017, 18, 85-111.	1.3	17
620	Multiple Chemical Sensitivity. , 2013, , 1379-1394.		3
621	Vivencias y sentimientos de los pacientes con Parkinson. EnfermerÃa ClÃnica, 2020, 30, 253-259.	0.1	3
622	Developmental exposure to the organochlorine pesticide dieldrin causes male-specific exacerbation of α-synuclein-preformed fibril-induced toxicity and motor deficits. Neurobiology of Disease, 2020, 141, 104947.	2.1	24
624	Phosphodiesterase Inhibitors as a New Therapeutic Approach for the Treatment of Parkinson's Disease. RSC Drug Discovery Series, 2013, , 294-307.	0.2	5
625	Quality of life in Parkinson's disease: A systematic review and metaâ€analysis of comparative studies. CNS Neuroscience and Therapeutics, 2021, 27, 270-279.	1.9	66
626	Non-genetic factors associated with the risk of Parkinson�s disease in Iranian patients. Functional Neurology, 2013, 28, 107-13.	1.3	9
627	Neurodegeneration Caused by Accumulation of an Oxidized Base Lesion, 8-oxoguanine, in Nuclear and Mitochondrial DNA: From Animal Models to Human Diseases. , 2017, , 523-556.		5
628	Detecting Apoptosis as a Clinical Endpoint for Proof of a Clinical Principle. Ophthalmologica, 2021, 244, 408-417.	1.0	5
629	Parkin ubiquitinates phosphoglycerate dehydrogenase to suppress serine synthesis and tumor progression. Journal of Clinical Investigation, 2020, 130, 3253-3269.	3.9	51
630	Parkin reinvents itself to regulate fatty acid metabolism by tagging CD36. Journal of Clinical Investigation, 2011, 121, 3389-3392.	3.9	18
631	Integrated analysis of mRNA expression profiling in Parkinson's Disease. Medical Science Monitor, 2020, 26, e920846.	0.5	7

#	Article	IF	CITATIONS
632	A Case-Control Study of the Protective Effect of Alcohol, Coffee, and Cigarette Consumption on Parkinson Disease Risk: Time-Since-Cessation Modifies the Effect of Tobacco Smoking. PLoS ONE, 2014, 9, e95297.	1.1	52
633	Occupational Complexity and Risk of Parkinson's Disease. PLoS ONE, 2014, 9, e106676.	1.1	19
634	Early-Life Factors and Risk of Parkinson's Disease: A Register-Based Cohort Study. PLoS ONE, 2016, 11, e0152841.	1.1	8
635	Digitized Spiral Drawing: A Possible Biomarker for Early Parkinson's Disease. PLoS ONE, 2016, 11, e0162799.	1.1	74
636	Statin adherence and the risk of Parkinson's disease: A population-based cohort study. PLoS ONE, 2017, 12, e0175054.	1.1	19
637	The Differential Diagnosis of Parkinson's Disease. , 0, , 109-128.		20
638	ExercÃcios terapêuticos domiciliares na doença de Parkinson: uma revisão integrativa. Revista Brasileira De Geriatria E Gerontologia, 2016, 19, 349-364.	0.1	10
640	Efecto de la exposición al pesticida rotenona sobre el desarrollo del sistema dopaminérgico nigro-estriatal en ratas. Salud Mental, 2013, 36, 1.	0.3	6
641	Increased risk of Parkinson's disease following tension-type headache: a nationwide population-based cohort study. Oncotarget, 2018, 9, 2148-2157.	0.8	6
642	Emerging preclinical pharmacological targets for Parkinson's disease. Oncotarget, 2016, 7, 29835-29863.	0.8	9
643	Protective Effects of the Caffeine Against Neurodegenerative Diseases. Current Medicinal Chemistry, 2019, 26, 5137-5151.	1.2	19
644	Peripheral Immunity, Immunoaging and Neuroinflammation in Parkinson's Disease. Current Medicinal Chemistry, 2019, 26, 3719-3753.	1.2	45
645	Aging and Neuroinflammatory Disorders: New Biomarkers and Therapeutic Targets. Current Pharmaceutical Design, 2019, 25, 4168-4174.	0.9	15
646	Design and Development of a Novel Supportive Care Product for the Treatment of Sialorrhea in Parkinson's Disease. Current Topics in Medicinal Chemistry, 2015, 15, 939-954.	1.0	2
647	Inflammatory and Cell Death Pathways in Brain and Peripheral Blood in Parkinson's Disease. CNS and Neurological Disorders - Drug Targets, 2015, 14, 313-324.	0.8	68
648	How Immune-inflammatory Processes Link CNS and Psychiatric Disorders: Classification and Treatment Implications. CNS and Neurological Disorders - Drug Targets, 2017, 16, 266-278.	0.8	33
649	Quantifying Short-Term Dynamics of Parkinson's Disease Using Self-reported Symptom Data From an Internet Social Network. Journal of Medical Internet Research, 2013, 15, e20.	2.1	34
650	3T MRI-SWI based volumetric analysis of the subthalamic and red nuclei in advanced Parkinson's disease. Journal of Neurosurgical Sciences, 2020, , .	0.3	2

#	Article	IF	CITATIONS
651	Prevalence of Parkinson Disease in Italy: a systematic review and meta-analysis. Acta Biomedica, 2020, 91, e2020088.	0.2	12
652	Visualisation of Parkinsonian, essential and physiological tremor planes in 3Dspace. Physiological Research, 2020, 69, 331-337.	0.4	2
653	The role of autophagy in Parkinson's disease. Neural Regeneration Research, 2012, 7, 141-5.	1.6	17
654	Magnetic resonance morphometry of the loss of gray matter volume in Parkinson's disease patients. Neural Regeneration Research, 2013, 8, 2557-65.	1.6	11
655	Bone Mineral Density and Serum Vitamin D Status in Parkinson's Disease: Are the Stage and Clinical Features of the Disease Important?. Neurology India, 2020, 68, 394.	0.2	9
656	Natural polyphenols effects on protein aggregates in Alzheimer's and Parkinson's prion-like diseases. Neural Regeneration Research, 2018, 13, 955.	1.6	98
657	ls aluminum exposure a risk factor for neurological disorders?. Journal of Research in Medical Sciences, 2018, 23, 51.	0.4	88
658	Association of four GSTs gene polymorphisms with Parkinson disease: A meta-analysis. Advances in Bioscience and Biotechnology (Print), 2014, 05, 100-107.	0.3	2
659	Current status and future challenges of deep brain stimulation in Switzerland. Swiss Medical Weekly, 2012, 142, w13570.	0.8	8
660	Occupational and recreational physical activity and Parkinson's disease in Denmark. Scandinavian Journal of Work, Environment and Health, 2017, 43, 210-216.	1.7	6
661	Usefulness of Transcranial Magnetic Stimulation to Assess Motor Function in Patients With Parkinsonism. Annals of Rehabilitation Medicine, 2016, 40, 81.	0.6	8
663	Herbicides and the Risk of Neurodegenerative Disease. , 0, , .		1
664	Mitochondrial dynamics in degenerative disease and disease models. Neuroscience Discovery, 2013, 1, 8.	0.6	3
665	The potential neuroprotective effect of diosmin in rotenone-induced model of Parkinson's disease in rats. European Journal of Pharmacology, 2022, 914, 174573.	1.7	10
666	Female Rats Are Resistant to Cognitive, Motor and Dopaminergic Deficits in the Reserpine-Induced Progressive Model of Parkinson's Disease. Frontiers in Aging Neuroscience, 2021, 13, 757714.	1.7	15
667	Gastric Helicobacter suis Infection Partially Protects against Neurotoxicity in A 6-OHDA Parkinson's Disease Mouse Model. International Journal of Molecular Sciences, 2021, 22, 11328.	1.8	2
668	Critical review of the Withania somnifera (L.) Dunal: ethnobotany, pharmacological efficacy, and commercialization significance in Africa. Bulletin of the National Research Centre, 2021, 45, 176.	0.7	21
669	Long-term Risk of Parkinson Disease Following Influenza and Other Infections. JAMA Neurology, 2021, 78, 1461.	4.5	45

#	ARTICLE Association of adverse effects with monoamine oxidase type B inhibitor and catechol-o-methyl	IF	CITATIONS
670	transferase inhibitor combination therapy in Parkinson's disease patients. Advances in Parkinson S Disease, 2012, 01, 5-10.	0.2	0
671	Catecholamines and Behavior. , 2012, , 434-440.		0
672	Impact of Medical and Neurological Disorders on Parasomnias. , 2013, , 302-305.		0
673	Can population genomics guide future therapeutic gene transfer strategies for Parkinson's disease?. Open Journal of Genetics, 2013, 03, 19-29.	0.1	0
675	Epidemiology and Risk Factors for Parasomnias. , 2013, , 157-164.		0
676	Rheumatoid Arthritis and Coexisting Parkinson's Disease a Report of 5 Cases. Electronic Journal of General Medicine, 2013, 10, .	0.3	0
678	Fusion Models and "Fusioning―in Parkinsonism: Protection and Restoration by Exercise. , 2014, , 2047-2063.		0
679	Links Between Paraquat and Parkinson's Disease. , 2014, , 819-842.		0
680	Involvement of the Cholinergic System in Levodopa-Induced Dyskinesia. , 2014, , 285-300.		0
681	Neuroepidemiology, Overview. , 2014, , 383-388.		Ο
682	Análisis de mutaciones en los genes PINK1 Y PARKIN en pacientes colombianos con enfermedad de Parkinson. Nova, 2014, 12, 15-21.	0.2	1
684	Two-Step Induction of Dopaminergic Neurone Differentiation of Leukapharesis-Derived Mesenchymal Stem Cells. American Journal of Bioscience and Bioengineering, 2015, 3, 7.	0.2	1
686	Addition of Exogenous α-Synuclein Oligomer up-regulates Divalent Metal Transporter-1 and Ferroportin-1 in BV2 Glial Cell Lines. International Journal of Sciences, 2016, 2, 54-60.	0.2	0
687	Cortical regulation of striatal projection neurons and interneurons in a Parkinson's disease rat model. Neural Regeneration Research, 2016, 11, 1969.	1.6	1
688	Quality of life of people with Parkinson's disease after treatment with non-immersive virtual reality. Acta Fisiátrica, 2016, 23, .	0.0	0
689	The Role of Chronic Inflammation in the Etiology of Parkinson's Disease. , 2016, , 63-74.		0
691	Targeting Nanoparticles to Brain: Impact of N-Methyl d-Aspartate Receptors. , 2017, , 199-220.		0
692	Epidemiological Methods for Studying Movement Disorders. , 2017, , 23-27.		О

#	Article	IF	CITATIONS
695	Development of Parkinsonism symptoms immediately after severe head injury. Journal of King Abdulaziz University, Islamic Economics, 2017, 22, 308-310.	0.5	2
696	Genes involved in the development of Parkinson. , 2017, 1, 039-051.		1
697	PARKINSON'S DISEASE IN DENTISTRY AND PERIODONTOLOGY. Cumhuriyet Dental Journal, 0, , 204-211.	0.1	0
698	Enriched environment elevates expression of growth associated protein-43 in the substantia nigra of SAMP8 mice. Neural Regeneration Research, 2018, 13, 1988.	1.6	7
700	Evaluation of Antioxidant Properties of Hydroalcoholic Extract of Purslane (Portulaca oleracea) and Its Protective Effect on 6-Hydroxydopamine Induced Hepatic Damage in Parkinsonian Male Rats. Majallah-i DÄnishgÄh-i Ì'UlÅ«m-i PizishkÄ«-i Qum, 2018, 12, 15-25.	0.2	0
701	The effectiveness of virtual reality and treadmill training in Parkinson's disease patients. MOJ Orthopedics & Rheumatology, 2018, 10, .	0.2	0
703	Motivation of elderly with Parkinson's disease submitted to functional training, aerobic exercise and exergame. Acta FisiAįtrica, 2018, 25, .	0.0	3
704	Motor Symptoms of Parkinson's Disease – A Review Literature. Neurophysiology and Rehabilitation, 2018, , 38-41.	0.0	1
705	Environmental Aspects of Alzheimer's and Parkinson's Diseases Neuropathologies. Advances in Environmental Engineering and Green Technologies Book Series, 2019, , 236-265.	0.3	1
706	MODELING OF PARKINSON'S DISEASE USING ENVIRONMENTAL NEUROTOXINS (REVIEW). Toxicological Review, 2019, , 9-15.	0.2	1
707	Pathogenesis, clinical features, and treatments of depression in Parkinson's disease. Nevrologiya, Neiropsikhiatriya, Psikhosomatika, 2019, 11, 93-99.	0.2	3
708	Novel Target Sites for Drug Screening: A Special Reference to Cancer, Rheumatoid Arthritis and Parkinson's Disease. Current Signal Transduction Therapy, 2019, 14, 107-121.	0.3	Ο
709	Sources of Intraspeaker Variation in Parkinsonian Speech Related to Speaking Style. Communications in Computer and Information Science, 2020, , 24-41.	0.4	0
711	Whole exome sequencing identified a new compound heterozygous <i>PRKN</i> mutation in a Chinese family with early-onset Parkinson's disease. Bioscience Reports, 2020, 40, .	1.1	3
713	Quality of Life and a Surveillant Endocannabinoid System. Frontiers in Neuroscience, 2021, 15, 747229.	1.4	19
714	Tryptophan 2,3-dioxygenase, a novel therapeutic target for Parkinson's disease. Expert Opinion on Therapeutic Targets, 2021, 25, 877-888.	1.5	4
715	Remote video-based outcome measures of patients with Parkinson's disease after deep brain stimulation using smartphones: a pilot study. Neurosurgical Focus, 2021, 51, E2.	1.0	9
717	Exposição a agrotóxicos na agricultura e doença de Parkinson em usuários de um serviço público de saAºde do ParanA¡, Brasil. Cadernos Saude Coletiva, 2020, 28, 567-578.	0.2	6

#	Article	IF	CITATIONS
718	Ambient Assisted Living At-Home Laboratory for Motor Status Diagnostics in Parkinson's Disease Patients and Aged People. Advances in Computer and Electrical Engineering Book Series, 2020, , 176-201.	0.2	1
719	Environmental and genetic risk factors for Parkinson's disease. , 2020, , 57-71.		0
721	Oxidative stress in rat heart mitochondria under a rotenone model of Parkinson' disease: a corrective effect of capicor treatment. Ukrainian Biochemical Journal, 2021, 93, 21-30.	0.1	2
722	Association of visual impairment with risk for future Parkinson's disease. EClinicalMedicine, 2021, 42, 101189.	3.2	6
723	Physiological Reactions of Patients with Parkinsonism to Simulated Microgravity Using "Dry― Immersion: A Pilot Study. Human Physiology, 2020, 46, 579-586.	0.1	1
725	Multiple System Atrophy (MSA) and smoking: a meta-analysis and mechanistic insights. Aging, 2020, 12, 21959-21970.	1.4	3
726	Genotype and age at Parkinson disease diagnosis. International Journal of Molecular Epidemiology and Genetics, 2013, 4, 61-9.	0.4	15
727	When to suspect a genetic syndrome. American Family Physician, 2012, 86, 826-33.	0.1	21
728	Demographic features and clinical characteristics of patients with Parkinson's disease in Isfahan, Iran. Iranian Journal of Neurology, 2018, 17, 6-10.	0.5	1
729	Protective Effects of Crude Plant Extracts against Aminochrome-induced toxicity in Human Astrocytoma Cells: Implications for Parkinson's Disease. Clinical Pharmacology and Translational Medicine, 2019, 3, 125-133.	0.3	2
730	Bee venom attenuates neurodegeneration and motor impairment and modulates the response to L-dopa or rasagiline in a mice model of Parkinson's disease. Iranian Journal of Basic Medical Sciences, 2020, 23, 1628-1638.	1.0	3
731	Respiratory disorders of Parkinson's disease. Journal of Neurophysiology, 2022, 127, 1-15.	0.9	11
732	Effects of Bolus Holding on Respiratory–Swallow Coordination in Parkinson's Disease. American Journal of Speech-Language Pathology, 2022, 31, 705-721.	0.9	10
733	Role of Metal Ions in Dopamine Oxidation. Journal of Chemical Education, 2021, 98, 4031-4036.	1.1	1
734	Minor hallucinations in isolated rapid eye movement sleep behavior disorder indicative of early phenoconversion: A preliminary study. Acta Neurologica Scandinavica, 2022, 145, 348-359.	1.0	5
735	Exposure to toxic occupations and their association with Parkinson's disease: a systematic review with meta-analysis. Reviews on Environmental Health, 2023, 38, 65-83.	1.1	8
736	Neurotoxicity and Underlying Mechanisms of Endogenous Neurotoxins. International Journal of Molecular Sciences, 2021, 22, 12805.	1.8	16
737	Effect of exercise therapy in multi disiciplainary approach of parkinson disorder: A short review. IP Indian Journal of Neurosciences, 2020, 6, 267-271.	0.0	0

# 738	ARTICLE Drug-induced depression. Neurologie Pro Praxi, 2021, 22, 303-307.	IF o.o	Citations 0
739	The risk of all-cause mortality, heart outcomes, cancer, and neurodegenerative disorders with cobalt-chrome-containing total hip arthroplasty implants. Bone and Joint Journal, 2022, , 1-9.	1.9	0
740	Detection of Freezing of Gait Using Convolutional Neural Networks and Data From Lower Limb Motion Sensors. IEEE Transactions on Biomedical Engineering, 2022, 69, 2256-2267.	2.5	16
741	Neuroprotective effects of indole-3-carbinol on the rotenone rat model of Parkinson's disease: Impact of the SIRT1-AMPK signaling pathway. Toxicology and Applied Pharmacology, 2022, 435, 115853.	1.3	14
742	Insights into the role of paraoxonase 2 in human pathophysiology. Journal of Biosciences, 2022, 47, 1.	0.5	13
743	The potential role of the cardiac MIBG scan in differentiating the drug-induced Parkinsonism from Parkinson's disease. Clinical Parkinsonism & Related Disorders, 2022, 6, 100130.	0.5	1
744	Comparison of the mass and amount of intramuscular non-contractile tissue of the trunk and lower extremity muscles between patients with Parkinson's disease and community-dwelling older adults. Neurological Sciences, 2022, , 1.	0.9	0
745	Multifactoriality of Parkinson's Disease as Explored Through Human Neural Stem Cells and Their Transplantation in Middle-Aged Parkinsonian Mice. Frontiers in Pharmacology, 2021, 12, 773925.	1.6	3
746	Current understandings and perspectives of petroleum hydrocarbons in Alzheimer's disease and Parkinson's disease: a global concern. Environmental Science and Pollution Research, 2022, 29, 10928-10949.	2.7	9
747	Consumers' Benefit—Risk Perception on Pesticides and Food Safety—A Survey in Greece. Agriculture (Switzerland), 2022, 12, 192.	1.4	16
748	Comparison of the effect of rotenone and 1‑methyl‑4‑phenyl‑1,2,3,6‑tetrahydropyridine on inducing chronic Parkinson's disease in mouse models. Molecular Medicine Reports, 2022, 25, .	1.1	10
749	Involvement of molecular chaperone in protein-misfolding brain diseases. Biomedicine and Pharmacotherapy, 2022, 147, 112647.	2.5	17
751	Assessment of retinal manifestations of Parkinson's disease using spectral domain optical coherence tomography: A study in Indian eyes. Indian Journal of Ophthalmology, 2022, 70, 448.	0.5	1
752	Comparative Analysis of CNN-based Deep Learning Approaches on Complex Activity Recognition. , 2022, ,		1
753	Parkinson's Detection Using RNN-Graph-LSTM with Optimization Based on Speech Signals. Computers, Materials and Continua, 2022, 72, 871-886.	1.5	4
754	A nationwide study of the incidence, prevalence and mortality of Parkinson's disease in the Norwegian population. Npj Parkinson's Disease, 2022, 8, 19.	2.5	25
755	A Comprehensive Review on Preclinical Evidence-based Neuroprotective Potential of Bacopa monnieri against Parkinson's Disease. Current Drug Targets, 2022, 23, 889-901.	1.0	4
756	Identification of Novel Noninvasive Diagnostics Biomarkers in the Parkinson's Diseases and Improving the Disease Classification Using Support Vector Machine. BioMed Research International, 2022, 2022, 1-8.	0.9	9

		CITATION REPORT		
#	Article		IF	CITATIONS
757	Gut-Derived Sterile Inflammation and Parkinson's Disease. Frontiers in Neurology, 2022	2, 13, 831090.	1.1	7
758	Association between Proton Pump Inhibitor Use and Parkinson's Disease in a Korea Pharmaceuticals, 2022, 15, 327.	n Population.	1.7	5
759	The risk of all-cause mortality, heart outcomes, cancer, and neurodegenerative disorder cobalt-chrome-containing total hip arthroplasty implants. Bone and Joint Journal, 2022,	s with 104-B, 359-367.	1.9	9
761	Does Nicotine from Passive Smoking and Foods Protect Against Parkinson's Diseas Nutrition and Food Science, 2022, 18, .	e?. Current	0.3	0
762	Orphan cytochrome P450 20a1 CRISPR/Cas9 mutants and neurobehavioral phenotype Scientific Reports, 2021, 11, 23892.	s in zebrafish.	1.6	5
763	Global Trends in the Incidence, Prevalence, and Years Lived With Disability of Parkinson 204 Countries/Territories From 1990 to 2019. Frontiers in Public Health, 2021, 9, 7768	's Disease in 47.	1.3	199
764	Prediction of neuro-degenerative disorders using sunflower optimisation algorithm and extreme learning machine: A case-study with Parkinson's and Alzheimer's disea Institution of Mechanical Engineers, Part H: Journal of Engineering in Medicine, 2022, 2	se. Proceedings of the	1.0	2
765	Novel Non-invasive Transcranial Electrical Stimulation for Parkinson's Disease. Fron Neuroscience, 2022, 14, 880897.	tiers in Aging	1.7	1
766	Dietary fat intake and risk of Parkinson disease: results from the Swedish National Marc European Journal of Epidemiology, 2022, 37, 603-613.	ch Cohort.	2.5	10
781	Gut microbiome-mediated regulation of neuroinflammation. Current Opinion in Immun 102177.	ology, 2022, 76,	2.4	30
782	Insights into the role of paraoxonase 2 in human pathophysiology Journal of Bioscienc	es, 2022, 47, .	0.5	0
783	Ambient Assisted Living At-Home Laboratory for Motor Status Diagnostics in Parkinson Patients and Aged People. , 2022, , 836-862.	's Disease		2
784	Dose–Response Association of Metformin with Parkinson's Disease Odds in Type Pharmaceutics, 2022, 14, 946.	2 Diabetes Mellitus.	2.0	9
785	Polymorphisms of Cytochromes P450 and Clutathione S-Transferases Synergistically M for Parkinson's Disease. Frontiers in Aging Neuroscience, 2022, 14, 888942.	odulate Risk	1.7	4
786	Effects of Palmitoylethanolamide on Neurodegenerative Diseases: A Review from Roder Biomolecules, 2022, 12, 667.	nts to Humans.	1.8	11
787	Risk evaluation of occupational exposure of southern Brazilian flower farmers to pestic potentially leading to cholinesterase inhibition and metals exposure. Environmental Toy Pharmacology, 2022, 93, 103874.		2.0	4
788	A cross-sectional study of Parkinson's disease and the prodromal phase in commur adults in eastern Japan. Clinical Parkinsonism & Related Disorders, 2022, 7, 100147.	ity-dwelling older	0.5	2
789	The Oxidation Stress, Mitochondrial-Pathway Apoptosis and the Antagonism Effects of in SH-SY5Y Cells via DTPP Induced Photodynamic Therapy. SSRN Electronic Journal, 0, ,		0.4	0

#	Article	IF	CITATIONS
790	Research Hotspots and Trends of Exercise on Parkinson's Disease: A Global Bibliometric Analysis From 2012 to 2021. Frontiers in Human Neuroscience, 2022, 16, .	1.0	1
791	Phytocannabinoids and Cannabis-Based Products as Alternative Pharmacotherapy in Neurodegenerative Diseases: From Hypothesis to Clinical Practice. Frontiers in Cellular Neuroscience, 0, 16, .	1.8	12
792	The Role of Transposable Elements of the Human Genome in Neuronal Function and Pathology. International Journal of Molecular Sciences, 2022, 23, 5847.	1.8	11
793	Peripheral blood inflammatory cytokines are associated with rapid eye movement sleep behavior disorder in Parkinson's disease. Neuroscience Letters, 2022, 782, 136692.	1.0	3
794	Effect of Physical Activity on Depression in Patients with Parkinson's Disease: A Systematic Review and Meta-Analysis. International Journal of Environmental Research and Public Health, 2022, 19, 6849.	1.2	8
795	Phosphorylated <scp>alphaâ€synuclein</scp> in <scp>lba1â€positive</scp> macrophages in the skin of patients with Parkinson's disease. Annals of Clinical and Translational Neurology, 0, , .	1.7	4
796	Insulin-like growth factor in Parkinson's disease is related to nonmotor symptoms and the volume of specific brain areas. Neuroscience Letters, 2022, 783, 136735.	1.0	5
797	Neuroprotective approaches to halt Parkinson's disease progression. Neurochemistry International, 2022, 158, 105380.	1.9	7
798	Novel nested patch-based feature extraction model for automated Parkinson's Disease symptom classification using MRI images. Computer Methods and Programs in Biomedicine, 2022, 224, 107030.	2.6	24
799	Insights Into the Role of Platelet-Derived Growth Factors: Implications for Parkinson's Disease Pathogenesis and Treatment. Frontiers in Aging Neuroscience, 0, 14, .	1.7	6
800	Burden of neurological disease. , 2023, , 1047-1064.		0
802	Parkinson disease and other synucleinopathies. , 2023, , 253-274.		0
803	The effects of physiotherapy treatments on dysphagia in Parkinson's disease: A systematic review of randomized controlled trials. Brain Research Bulletin, 2022, 188, 59-66.	1.4	4
804	Impact of aging on animal models of Parkinson's disease. Frontiers in Aging Neuroscience, 0, 14, .	1.7	18
805	Head-Space SPME for the Analysis of Organophosphorus Insecticides by Novel Silica IL-Based Fibers in Real Samples. Molecules, 2022, 27, 4688.	1.7	5
806	The oxidative stress, mitochondrial pathway apoptosis, and the antagonistic effects of chrysophanol in SH-SY5Y cells via DTPP-induced photodynamic therapy. Photodiagnosis and Photodynamic Therapy, 2022, 40, 103062.	1.3	1
807	Risk Factors of Parkinson's Disease: A Case-Control Study in Moroccan Patients. Archives of Neuroscience, 2022, 9, .	0.1	1
808	Multi-predictor modeling for predicting early Parkinson's disease and non-motor symptoms progression. Frontiers in Aging Neuroscience, 0, 14, .	1.7	1

#	Article	IF	CITATIONS
809	Neurotoxicity of pesticides – A link to neurodegeneration. Ecotoxicology and Environmental Safety, 2022, 243, 113972.	2.9	34
811	Pose-Based Tremor Classification forÂParkinson's Disease Diagnosis fromÂVideo. Lecture Notes in Computer Science, 2022, , 489-499.	1.0	3
812	Stress system and related biomarkers in Parkinson's disease. Advances in Clinical Chemistry, 2022, , .	1.8	1
813	The Neurodegenerative Elderly Syndrome (NES) hypothesis: Alzheimer and Parkinson are two faces of the same disease. IBRO Neuroscience Reports, 2022, 13, 330-343.	0.7	4
815	Neuroprotective Effects of gH625-lipoPACAP in an In Vitro Fluid Dynamic Model of Parkinson's Disease. Biomedicines, 2022, 10, 2644.	1.4	2
816	Association between gout and the development of Parkinson's disease: a systematic review and meta-analysis. BMC Neurology, 2022, 22, .	0.8	1
817	Gait Characteristics Analyzed with Smartphone IMU Sensors in Subjects with Parkinsonism under the Conditions of "Dry―Immersion. Sensors, 2022, 22, 7915.	2.1	3
818	Inflammation on the crossword of Parkinson's disease and COVID-19. Indian Journal of Clinical Anatomy and Physiology, 2022, 9, 166-173.	0.1	1
819	Putamen Atrophy Is a Possible Clinical Evaluation Index for Parkinson's Disease Using Human Brain Magnetic Resonance Imaging. Journal of Imaging, 2022, 8, 299.	1.7	1
820	Correlation between serum IGF-1 and EGF levels and neuropsychiatric and cognitive in Parkinson's disease patients. Neurological Sciences, 2023, 44, 881-887.	0.9	4
821	IN SILICO ANALYSIS OF THE POTENTIAL ROLE OF SRY GENE IN PARKINSON'S DISEASE. Süleyman Demirel Üniversitesi Tıp Fakültesi Dergisi, 2023, 30, 19-24.	0.0	0
822	Effects of Insole with Toe-Grip Bar on Barefoot Balance and Walking Function in Patients with Parkinson's Disease: A Randomized Controlled Trial. Geriatrics (Switzerland), 2022, 7, 128.	0.6	2
823	Assessing the association between white matter lesions and Parkinson's disease. Neurological Sciences, 2023, 44, 897-903.	0.9	2
824	6-Hydroxydopamine (6-OHDA) rodent model of Parkinson's disease: Investigating neural control of cardiorespiratory function. , 2023, , 493-506.		0
825	Chronic effects of different exercise types on brain activity in healthy older adults and those with Parkinson's disease: A systematic review. Frontiers in Physiology, 0, 13, .	1.3	1
826	Modeling neuromuscular diseases in zebrafish. Frontiers in Molecular Neuroscience, 0, 15, .	1.4	2
827	Prevalence of Malnutrition in Patients with Parkinson's Disease: A Systematic Review. Nutrients, 2022, 14, 5194.	1.7	5
828	Conformational change of α-synuclein fibrils in cerebrospinal fluid from different clinical phases of Parkinson's disease. Structure, 2023, 31, 78-87.e5.	1.6	13

#	Article	IF	CITATIONS
829	Technological support for people with Parkinson's disease: a narrative review. Journal of Gerontology and Geriatrics, 0, , 1-15.	0.2	1
830	Gut Microbiota Changes and Parkinson's Disease: What Do We Know, Which Avenues Ahead. Healthy Ageing and Longevity, 2023, , 257-278.	0.2	0
831	Effects of Music-Based Interventions on Motor and Non-Motor Symptoms in Patients with Parkinson's Disease: A Systematic Review and Meta-Analysis. International Journal of Environmental Research and Public Health, 2023, 20, 1046.	1.2	7
832	l-carnitine: Nutrition, pathology, and health benefits. Saudi Journal of Biological Sciences, 2023, 30, 103555.	1.8	13
833	Barbigerone Potentially Alleviates Rotenone-Activated Parkinson's Disease in a Rodent Model by Reducing Oxidative Stress and Neuroinflammatory Cytokines. ACS Omega, 2023, 8, 4608-4615.	1.6	5
834	Protective Effect of Hirsutidin against Rotenone-Induced Parkinsonism via Inhibition of Caspase-3/Interleukins-6 and 11². ACS Omega, 2023, 8, 13016-13025.	1.6	2
835	Prevalence and causative drugs of drug-induced Parkinsonism in pediatric patients. European Child and Adolescent Psychiatry, 0, , .	2.8	0
836	Progesterone exerts a neuroprotective action in a Parkinson's disease human cell model through membrane progesterone receptor α (mPRα/PAQR7). Frontiers in Endocrinology, 0, 14, .	1.5	2
837	Voice feature description of Parkinson's disease based on co-occurrence direction attribute topology. Engineering Applications of Artificial Intelligence, 2023, 122, 106097.	4.3	6
838	Aspalathin and linearthin from Aspalathus linearis (Rooibos) protect SH-SY5Y cells from MPP+-induced neuronal toxicity. South African Journal of Botany, 2023, 157, 53-63.	1.2	0
839	Effects of aquatic exercise on the improvement of lower-extremity motor function and quality of life in patients with Parkinson's disease: A meta-analysis. Frontiers in Physiology, 0, 14, .	1.3	2
840	Melatonin and Health: Insights of Melatonin Action, Biological Functions, and Associated Disorders. Cellular and Molecular Neurobiology, 2023, 43, 2437-2458.	1.7	27
841	Combined chronic copper exposure and aging lead to neurotoxicity in vivo. NeuroToxicology, 2023, 95, 181-192.	1.4	4
842	Disease-gene prediction based on preserving structure network embedding. Frontiers in Aging Neuroscience, 0, 15, .	1.7	0
844	β2â€Adrenoreceptor Agonists, Montelukast, and Parkinson Disease Risk. Annals of Neurology, 2023, 93, 1023-1028.	2.8	2
845	Oral and intestinal dysbiosis in Parkinson's disease. Revue Neurologique, 2023, 179, 937-946.	0.6	4
846	Complete denture rehabilitation for a patient with Parkinson's disease using clinical strategies: A case report. Special Care in Dentistry, 2024, 44, 124-129.	0.4	0
853	Gastrointestinal disorders in Parkinson's disease and other Lewy body diseases. Npj Parkinson's Disease, 2023, 9, .	2.5	3

#	Article	IF	CITATIONS
854	Exercise and Parkinson's disease: Linking in the cannabinoid type 1 (CB1) and type 2 (CB2) and mu-opioid receptors. , 2023, , 137-147.		0
860	Capsaicin, The Vanilloid Receptor TRPV1 Agonist in Neuroprotection: Mechanisms Involved and Significance. Neurochemical Research, 2023, 48, 3296-3315.	1.6	9
861	Pesticide Exposure as a Risk Factor for Parkinson's Disease. Advances in Medical Diagnosis, Treatment, and Care, 2023, , 182-195.	0.1	1
864	Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	23
865	Diagnostic Biomarkers of Parkinson's Disease. Advances in Medical Diagnosis, Treatment, and Care, 2023, , 64-80.	0.1	0
869	Epidemiology of Parkinson's Disease. Advances in Medical Diagnosis, Treatment, and Care, 2023, , 1-12.	0.1	1
887	AUTOMA 2.0: a Wearable Platform to Assess the Muscular Activity of Upper and Lower Limbs in Patients Affected by Neuromuscular Disorders. , 2023, , .		0